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ABSTRACT 
 
 
Cancer immunotherapy has led to significant improvement in the survival of patients with 
previously untreatable malignancies. The use of therapeutic vaccines is a promising form of 
immunotherapy, but their efficacy remains ambiguous. Much of the difficulty in identifying the 
optimal formulation and delivery is related to the complicated nature of the immune response, 
where it is uncertain which aspects would be most effective in destroying cancer cells. In this 
thesis, a novel polymeric delivery system, involving poly (caprolactone)-co-poly (ortho ester) 
[PCL-POE], was used to deliver tumor antigens and adjuvants in a controlled manner. We 
hypothesized that persistent release of tumor antigens from the biodegradable polymer would 
result in an increase in the number and persistence of anti-tumor lymphocytes in the effector state. 
To test this hypothesis, vaccines were administered to mice and the time dependent 
immunological response was evaluated. The polymeric delivery system resulted in an in vitro 
release profile characterized by a burst release of both antigen and adjuvant followed, in both 
cases, by a much slower phase of release. We also observed that the slow release provided by the 
PCL-POE polymer stimulated prolonged maturation of dendritic cells, activation and persistence 
of anti-OVA antibodies and antigen-specific T cells following a single vaccination. The vaccine 
system was also tested in a mouse model of glioblastoma multiforme (GBM). We observed a 
significant, potentially translatable increase in overall survival. 
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INTRODUCTION 
Brain Tumors 
Incidence, types, and prognosis 
A glioma is the general term used for a primary brain tumor.  It can arise from any of 
three types of glial cells of the central nervous system, which include astrocytes, 
oligodendrocytes, and ependymal cells. Of special interest are the astrocytes that make up the 
supportive tissue of the brain. Tumors stemming from astrocytes are called astrocytomas and are 
graded according to criteria established by the World Health Organization (WHO) criteria. As an 
initial division, tumors are graded as being either benign or malignant. For malignant tumors, 
grade I (low grade) astrocytomas are more localized, have a slower growth rate, and carry a better 
prognosis. They are also most common in children. Astrocytomas in grades II through IV are 
progressively more severe as the tumor is much more aggressive and invasive. The highest grade 
(IV) astrocytomas may be referred to as a Grade IV Glioblastoma or, most commonly, 
Glioblastoma Multiforme (GBM). GBM is the most common primary brain malignancy in adults, 
and carries an extremely poor prognosis.  An estimated 18,000 people die each year in the United 
States from GBM.1 
 
Current treatment of brain tumors 
Historically, the standard of care for GBM was surgical resection of the tumor followed 
by brain irradiation. With this approach, the median survival time following diagnosis was less 
than 12 months. In 2005, Stupp, et al2 published the results from a phase III clinical trial that 
added temozolomide, an alkylating chemotherapeutic agent, to the combination of surgery and 
radiation. With this combination regimen, the median survival of patients with GBM was 
extended to approximately 15-18 months post-diagnosis. As such, this approach became the new 
standard of care and is presently used for comparison of new treatments. Given the mortality rate, 
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considerable effort has been devoted to increasing survival times in patients; however, progress 
has remained elusive. 
The dismal prognosis of gliomas with implementing standard of care treatment has driven 
the search for innovative methods for curing patients with GMB.  One promising avenue is 
immunotherapy.  In the following sections, the current state of immunotherapy of GBM is 
addressed.  For background, the salient features of the immune system are presented including the 
humoral and cell mediated response.  Particular attention is given to the impact of the presence of 
persistent antigens on the magnitude and kinetics of the immune response, the role of a 
controlled-release vaccine in providing persistent antigens, and the effect of the magnitude and 
kinetics of the immune response on the survival of the glioma mouse model. 
 
Fundamentals of the immune system 
Antibody (humoral) immune response 
B Cells 
Immunity and the immune response rely on many cells and specialized entities in a 
complex interactive manner. The adaptive immune response is of particular interest, and therefore 
the general discussion begins with the humoral immune response. This arm of the immune system 
is comprised of B cells and antibodies, which is distinct from the cell mediated arm, albeit these 
two arms are interactive.  
All naïve B cells express on their surface a B cell receptor (BCR), which is a membrane 
bound antibody. Unlike T lymphocyte receptors, BCRs recognized and bind antigens that are 
often portions of a three dimensional (3D) structure of large macromolecules, including many 
proteins and polysaccharides. Like T cells, B cells are present in secondary lymphoid organs to 
bind the specific antigen and thereby form an antibody-antigen cognate. Naïve B cells circulate 
through the follicles of the lymph nodes and spleen where they encounter foreign proteins 
brought there by direct lymphatic drainage.3 
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A few naïve B cells will express a BCR that is specific for a single antigen. In the 
presence of a particular antigen (i.e. infection), naïve B cells with B cell receptors specific for the 
antigen bind the antigen. This, in turn, stimulates the intracellular portion of the BCR to transduce 
a signal that causes the B cell to migrate to the edge of the lymph node, that is, the T cell area.4 
This binding also results in the B cell internalizing the antigen by receptor mediated endocytosis. 
Within the endosome of the B cell, the foreign protein is degraded into peptides, followed by the 
loading of immunogenic peptide epitopes onto MHCII. This ultimately leads to expression of the 
peptide:MHCII complex on the surface of the B cell. In this way, B cells are acting as a type of 
antigen presenting cell. Still localized at the T cell border of the lymph node, the peptide:MHCII 
expressing B cell(s) will bind to CD4+ (helper) T cells that have T cell receptors (TCRs) specific 
for the same antigen (peptide:MHCII complex) expressed by the B cell. This interaction causes 
activation of the antigen-specific CD4 T cell, which will then secrete cytokines that stimulate the 
antigen-specific B cell to proliferate and differentiate into effector cells. The result is in an 
exponential increase in the number of B cells specific for the particular antigen. In addition, 
secondary lymphoid organs begin to form germinal centers within the lymph node.  
A differentiated B cell has one of three potential effector cell fates; short-lived plasma 
cell5, germinal center (GC) B cell6, or memory B cell.7 Upon initial activation of the naïve 
antigen-specific B cell, the outcome of becoming a short-lived plasma cell or GC B cell is 
governed by transcriptional regulation. B cells that up-regulate the transcription factor Blimp-1 
exit the germinal center and differentiate into short-lived, antibody-secreting plasma cells. During 
the course of the initial infection, plasma cells or effector B cells produce and secrete large 
quantities of antibodies, the secreted form the B cell receptor. This process can occur within a few 
hours of the initial antigen exposure. Short-lived plasma cells are generally disseminated into 
blood and tissues, where they secrete millions of copies of the clonal antibody. The antibodies 
secreted from the short-lived plasma cells are typically the IgM (shorter half-life) isotype, which 
have a relatively lower affinity. However, short-lived plasma cells and associated secreted 
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antibodies are essential for clearance of the initial infection (i.e. acute response to antigen 
exposure).  
B cells that up-regulate the Bcl-6 transcription factor migrate into the germinal center of 
the follicle and interact with another type of CD4 T cell, the follicular helper T cell.8 The 
interaction of the B cell with the follicular CD4 T cell promotes proliferation of the B cells and 
stimulates somatic hypermutation9, such that those that acquire “positive” mutations develop a 
higher affinity for the antigen.10 Somatic hypermutation is the occurrence of hundreds of 
thousands of mutations within the complementarity-determining regions of the immunglobulin 
genes within the B cell nucleus, which encode for the variable region of antibodies. B cells that 
have undergone somatic hypermutation must compete for available antigens over the course of 
the immune response (or infection). Specialized dendritic cells within the germinal center 
follicles of the secondary lymphoid organs, called follicluar dendritic cells, present antigen to the 
B cells. The progeny B cells with the highest affinity for the specific antigen are selected to 
survive. Those, which bind antigen with lower affinity, are deleted due to the competition for the 
limited antigen. With each round of selection, the secreted antibodies have greater affinity for the 
antigen. This process is referred to as affinity maturation.11  As a result of somatic hypermutation 
and affinity maturation, B cells that develop the highest affinity B cell receptors out-compete 
those without the receptors and emerge from the germinal center as either memory B cells or 
long-lived plasma cells.  These two effector cell types are the core of immunological B cell 
memory.  
The long-lived plasma cells migrate to the bone marrow, where they take up residence 
and continuously produce and secrete large quantities of clonal antibodies. Along with affinity 
maturation, plasma cells undergo isotype switching, generally from an IgM to an IgG isotype.  As 
such, these cells persist as effector cells that secrete IgG (longer half-life) antibodies of high 
affinity for their antigen.  Unlike memory B cells, long-lived plasma cells express little or no 
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BCRs. Thus, long-lived plasma cells are not stimulated either to divide or increase the rate of 
antibody production in the presence of antigen (i.e. they persist independent of antigen).  
Memory B cells are localized primarily within the secondary lymphoid organs. Like the 
long-lived plasma cells, they have undergone the processes of affinity maturation and somatic 
hypermutation, and thus express a high affinity B-cell receptor (BCR). However, they do not 
secrete antibodies in the absence of antigen. In response to secondary infection or antigen re-
exposure, they mediate rapid recall responses by quickly dividing and differentiating into 
antibody-secreting plasma cells, while also simultaneously replenishing the memory B cell pool. 
This amplified and exquisitely selective antibody production is the hallmark of the secondary 
antibody response. 
 
Antibodies 
 Antibodies are a key component of adaptive immunity and the response to vaccination. 
Antibodies are the secreted immunoglobulins that are initially present at the surface as a B cell 
receptor. Biochemically, antibodies are Y-shaped proteins consisting of four polypeptide chains, 
of which two are referred to as heavy (longer) chains and two as light (shorter) chains. At the end 
of the two “arms” of the antibody, both the light and heavy chains combine to form the variable, 
antigen specific, portion of the antibody. Together, the end of one heavy and one light chain 
create a pocket, uniquely shaped with the appropriate chemical moieties, to bind a specific 
antigen.  The stem of the Y-shaped antibody is identical in all antibodies of the same class, is 
independent of antigen specificity, and is called the constant region.  
The known classes of antibodies include immunoglobulin M (IgM), IgD, IgE, IgA, and 
IgG. The constant region is the same for each isotope of immunoglobulin.  The different constant 
regions among the classes of antibodies allows the antibody to interact with cells of the innate 
immune system, including natural killer (NK) cells, complement proteins, neutrophils and mast 
cells, which in turn, are involved in the destruction or removal of the bound antigen. Along with 
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affinity maturation, antibody class switching is simultaneously occurring during the antigen-
dependent phase of B cell development. Antibody class switching is a mechanism that changes a 
B cell's production of antibody from one class to another, for example, from the IgM isotype class 
to the IgG isotype class. During this process, the constant region portion of the antibody heavy 
chain is changed, but the variable region of the heavy chain remains unchanged. The IgG class of 
antibodies is the most abundant antibody isotype found in the blood and extracellular fluid, 
representing approximately 75% of serum immunoglobulins in humans. IgG plays a vital role in 
the immune response to bacteria, fungi, and viruses and does so by a variety of mechanisms that 
include opsonization (coating the pathogen for recognition by cytotoxic immune cells), binding 
and immobilizing the pathogen, and triggering the initial step of antibody-dependent cellular 
cytotoxicity. 
 
T Cell-mediated immune responses 
T-lymphocyte 
 Equally important to antibodies in the humoral response are T lymphocytes, which are 
the key cells in the cell-mediated arm of the adaptive immune system. Two general subtypes of T 
lymphocytes exist, CD4-expressing (CD4) T cells and CD8-expressing (CD8) T cells. CD8 T 
cells are often referred to as cytotoxic T lymphocytes due to their ability to exert direct cytotoxic 
effects on antigen-expressing target cells. CD4 T cells are generally known as helper T cells due 
to their role in boosting the antibody response to specific antigens by interaction with antigen-
specific B cells. However, numerous other roles for distinct subtypes of CD4 T cells exist, 
including some direct cytotoxic function that have been shown to play a role in anti-tumor 
immunity. Like naïve B cells with their B cell receptor, each naïve T cell has a T cell receptor 
(TCR) expressed on its surface that is specific for a given antigen. Unlike B cell and BCRs, TCRs 
can only recognize antigens when bound to the surface of a major histocompatibility complex 
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(MHC). Thus, the antigen that is recognized by a given TCR is a complex of a short 
immunogenic peptide bound to an MHC protein molecule.  
MHC molecules exist in two forms, MHCI and MHCII. MHCI is expressed on all 
nucleated cells, including cancer cells as well as antigen presenting cells (APCs) of the immune 
system. In contrast, MHCII expression is limited to APCs, including B cells, macrophages, and 
dendritic cells (DCs). MHCI proteins bind CD8 T cell epitopes and are presented as a complex 
with the epitope on the surface cells. The peptide:MHCI complex on the surface of a cell is then 
recognized and bound by a naïve CD8 T cell specific for the antigen complex. MHCII proteins 
bind CD4 T cell epitopes and are presented as a complex with the epitope on the surface of APCs. 
The peptide:MHCII complex expressed on the surface of the APC is then recognized and bound 
by a naïve CD4 T cell specific for the antigen complex. Thus, as a rule, peptide-MHCI complexes 
are recognized by TCRs on CD8 T cells, while peptide-MHCII complexes are recognized by 
TCRs on CD4 T cells (white blood cells of the immune system, also called T-helper cells,) which 
send signals to CD8 killer cells to destroy the invading organisms.  
The CD8 and CD4 peptide epitope bound by MHCI and MHCII proteins, respectively, is 
referred to as minimum peptide epitope. This name reflects that it is the shortest amino acid 
sequence, the final digest, able to fit into the peptide binding groove of the MHC protein. 
Minimum peptide epitopes that are bound by MHCI are either 8 or 9 amino acids, while 
minimum peptide epitopes that are bound by MHCII proteins are approximately 14 to 17 amino 
acids. In most cells, including cancer cells, MHCI molecules only bind to peptides derived from 
intracellular proteins that are cleaved in the cytosol and trafficked into the endoplasmic reticulum 
(ER) where the binding occurs. Peptide-MHCI complexes are then transported in vesicles to the 
plasma membrane and expressed on the cell surface. Therefore, for CD8 epitopes within a protein 
to gain access to the MHCI pathway, they must enter the cell by pinocytosis or be located within 
the cell itself, for example an intracellular infection or certain cancer proteins. CD4 epitopes gain 
access to the MHCII processing pathway by undergoing endocytosis into the endolysosomal 
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system. Inside the endolysosomes, the proteins are digested, and the endolysosome merges with 
another vesicle carrying an MHCII molecule.12 Thus, the pathways by which CD4 and CD8 
epitopes are presented on their respective MHC molecules differ. 
 
Dendritic cells 
Dendritic cells are exceptional as antigen presenting cells. DCs can internalize 
extracellular proteins into endolysosomes and translocate them into the cytosol for processing and 
peptide binding to MHCI molecules in a process called cross-presentation.13   This is shown in 
Figure 1. Antigen cross-presentation is critical to the development of effective anti-cancer 
vaccines, because it can process CD8 antigens that enter into DCs by receptor-mediated 
endocytosis, a common pathway for entry of exogenous proteins into immune cells.14 Thus, the 
ability of DCs to express both MHCI and MHCII molecules as well as process and present 
antigen by any of three different pathways is what has led to their designation as “professional 
APCs”. 
DCs are part of the innate immune system. They are widespread throughout the body and 
are often localized at entry points of infection, e.g. skin. In this strategic location, DCs can 
continuously sample their environment for the presence of foreign bodies, which includes the 
draining lymph nodes. These acting sentinel DCs are in their immature state and are specialized 
for phagocytosis. Upon uptake of extracellular material, the DC will direct the immune system 
towards a path of either tolerance, in response to “self” antigens, or activation, in response to 
“foreign” antigens. In either case, DCs are able to stimulate the appropriate immune response by 
up-regulating MHC proteins as well as other co-stimulatory molecules. The co-stimulatory 
molecules are then recognized as immunostimulatory or immunosuppressive by other cells of the 
immune system, thereby leading to an “activation” or a “tolerant” immune response, respectively.  
Following uptake of foreign antigens, DCs will up-regulate activating co-stimulatory 
molecules, such as CD80 and CD86, along with the appropriate MHC protein. These changes are 
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the hallmarks of the transition of DCs into their mature state, and their ability to phagocytose 
material is decreased coincident with increased specialization for T cell activation. The mature 
DCs present peptide-MHCI or peptide-MHCII complexes to CD8 and CD4 T cells, respectively, 
as well as the appropriate co-stimulatory molecules. The co-stimulatory molecules are recognized 
and bound by the CD28 ligand on the surface of T cells. Simultaneous binding of the 
pepide:MHC complex on the DC surface with the TCR and CD80/86 co-stimulatory molecules 
on the surface of DCs with CD28 on the T cell surface is required for T cell activation. With 
activation, T cells undergo extensive proliferation with their progeny migrating from the lymph 
nodes to the site of the foreign material.   
 
Phases of the Immune Response 
The immune response to an acute exposure of foreign peptide:MHC (antigen) complexes 
involves three distinct phases. The first, expansion phase, occurs over the initial seven days and 
involves rapid proliferation and differentiation of antigen-specific naïve T cells into effector T 
cells. Antigen-specific T cells that have proceeded through an entire proliferative cycle, 
approximately ten to thirteen cell divisions, are then classified as antigen-specific effector CD8 T 
cells based on their ability to traffic to sites of infection and producing anti-inflammatory 
lymphokines. A single clone of effector cells specific for a single antigen often develops 
heterogeneity in their cytotoxic patterns. The cytokines secreted by effector T cells include 
interferon gamma (IFN-γ), tumor necrosis factor beta (TNF-β), and/or interleukin 2 (IL-2). In 
addition to the differences in cytokine production and secretion, effector T cells secrete a variety 
of toxic mediators, which may include perforin or granzyme.15 Effector T cells, generated 
following antigenic stimulation of naïve cells, extravasate into peripheral tissues to rapidly 
control infection by elaboration of their effector functions and target cell identification and 
eradication. Unlike memory T cells, which are able to persist in the absence of antigen, effector T 
cell functions are maintained only in the presence of antigen.16  
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The expansion phase is followed by a contraction phase that results in the elimination of 
approximately 90 percent of the antigen-specific effector T cells over a two to three week period. 
The effector cells undergo apoptosis and are cleared from the circulation by macrophages of the 
reticuloendothelial system (RES). The surviving effector cells undergo further differentiation into 
memory cells.17  
Following the contraction phase, the memory or maintenance phase occurs.  Here, the 
pool of stable, highly polyfunctional memory T cells are found to persist indefinitely by 
continuous replication and self-renewal. Maintenance of the antigen-specific memory population 
can occur in both the presence and absence of antigen. In the absence of antigen, memory T cells 
persist in response to homeostatic signals, such as the cytokines IL-7 and IL-15, which are 
secreted in the secondary lymphoid organs.  
 
Effector & Memory T cells 
In the recent decade, much research has gone into studying the heterogeneic and 
qualitative nature of antigen-specific memory cells. Although the number of distinct types of 
memory T cells continues to increase, a generally accepted finding is that two types of memory T 
cells exist, the effector memory (TEM) and central memory (TCM) T cells.18 Phenotypically, TEM 
and TCM cells are characterized by the expression of L-selectin (CD62L) and CC-chemokine 
receptor 7 (CCR7), which play a key role in determining the trafficking properties T cells. Central 
memory CD8 T cells, characterized by high levels of expression of CD62L and CCR7, are 
localized primary within the secondary lymphoid organs and have limited effector capabilities. 
They are reported to have stem cell-like properties of self-renewal. Thus, upon re-exposure to 
their cognate antigen, they undergo rapid proliferation and differentiation into effector CD8 T 
cells. In contrast, effector memory CD8 T cells, characterized by a lack of expression of CD62L 
and CCR7, proliferate much more rapidly upon re-exposure to antigen and are localized primarily 
in the peripheral tissues. Their location at the site of disease allows for the rapid attack upon 
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encountering target cells. In the case of cancer, newly dividing cancer cells could be identified 
and eradicated much more rapidly due to the presence of the antigen-specific effector memory 
CD8 T cells. 
For immunotherapy of GBM, migration through the blood stream to the location of a 
tumor is a critical step. Whereas the brain was once believed to be an immune privileged site, an 
abundance of new evidence has demonstrated the ability of innate immune cells effector T cells, 
plasma cells19 and antibodies to traffic into the brain and to the site of the tumor.20,21 
 
Cancer Vaccines 
Prophylactic vs therapeutic vaccines 
Vaccines may be either prophylactic, intended to prevent disease, or therapeutic, intended 
to treat disease. Prophylactic vaccines, such as measles, small pox, and polio have a long history, 
whereas the use of therapeutic vaccines is a much more recent development. The aim of 
therapeutic cancer vaccines is to harness the specificity and expansive capabilities of the immune 
system by stimulating a small number of tumor-specific lymphocytes to proliferate into a large 
number of tumor-specific effector lymphocytes. 
The potential impact of therapeutic vaccines for treatment of active disease states is 
beginning to be realized in both the scientific and medical communities. This is evident by the 
introduction of Sipuleucel-T22 for treating prostate cancer, which is the first therapeutic vaccine 
ever to receive FDA approval (2010).  Presently, there are more than 100 of such vaccines in 
ongoing phase III trials (clinicaltrials.gov “search terms: cancer AND vaccine).  A major 
advantage of therapeutic vaccines over other types of immunotherapy is the potential for immune 
memory. As described above, the T lymphocytes of the immune system undergo activation and 
proliferation, with the peak response in the number of antigen-specific T cells occurring at 
approximately day 7 in response to acute exposure to foreign antigens,. This is followed by a 
contraction phase over the next 3-5 days that results in the elimination (apoptotic death) of 
12 
 
approximately 90% of the antigen-specific T cells. The remaining 10% of the antigen-specific 
memory cells23 are capable of responding much more rapidly upon re-encounter with the same 
antigen. Theoretically, memory B and T cells, along with innate immune cells, would be able to 
continuously survey the entire body for new or metastasized tumor cells. Memory cells thus 
provide the potential for achieving a complete cure for cancer. That is, complete elimination of all 
cancer cells for a life time.  No other therapy holds this promise.  The key to realize the full 
potential benefit of therapeutic cancer vaccines lies in the phenomenon of immune memory. 
Although therapeutic vaccines are formulated in a similar manner to prophylactic 
vaccines, the treatment objective is unique. The aim of prophylactic vaccines is to develop an 
immune response to a disease or infection, so that if the pathogen is encountered, then the 
immune system is already primed to mount an effective immune response and eliminate the 
pathogen. Therapeutic vaccines, in contrast, are intended to stimulate an immune response against 
an already established disease. While the potential for development of prophylactic cancer 
vaccines exists, much work remains in identifying and delivering antigens that lead to the 
development of efficacious immune memory.  
 
Adjuvants in vaccine formulations 
In formulating vaccines, an adjuvant is often included. Adjuvants are designed to non-
specifically activate the cells of the immune system. With the growing interest in both 
prophylactic and therapeutic vaccines in the past decade, development of novel adjuvants is a key 
goal to create a more potent and efficacious response to the antigen in the vaccine.  Adjuvants are 
classified as one of three types, particulate formulations, immunostimulatory, or a combination of 
immunostimulatory molecules formulated within particulate systems.24 Particulate formulations 
or delivery vehicles function as adjuvants by more effectively presenting antigens to the immune 
system.   
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In contrast, immunostimulatory molecules directly activate innate immune receptors of 
the immune system. Immunostimulatory adjuvants contain “danger signals”, which are pattern-
associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs).25 Both 
PAMPs and DAMPs are pathogen-associated products with conserved molecular motifs or 
signatures of cell stress/tissue damage and are recognized and bound by pattern-recognition 
receptor (PRRs).26 PRRs are expressed by many different cells of the immune system as well as 
by some non-immune cells. PRRs include the class of toll-like receptors (TLR)27, which comprise 
proteins that play a key role in the innate immune system. TLRs are transmembrane receptors 
expressed by the phagocytic cells of the immune system, including macrophages, dendritic cells, 
and neutrophils. TLRs may span the cell membrane with the ligand binding site facing externally 
or span the endosomal membrane with the ligand binding site facing into the endosome. Ten total 
TLRs (TLR-1 through TLR-10) have been recognized to date and are distinguished by their 
activation of a particular set of signaling pathways and the resulting biological effects.  When 
activated, they stimulate signaling that leads to the activation of key transcription factors, most 
commonly nuclear factor-κB (NF-κB).28 These transcription factors, in turn, stimulate gene 
expression programs that lead to secretion of cytokines and chemokines, enhanced antigen 
presentation capacity, and migration to lymphoid tissues where the DCs interact with T cells and 
B cells to initiate and shape the adaptive immune response.29 
In this thesis, resiquimod was studied as a potential immunostimulatory molecule.  
Resiquimod is an analogue of the RNA base guanine and TLR-7 and TLR-8 agonist. TLR-7 and 
TLR-8 are natural receptors for viral RNA and are expressed on the endosomal membrane. Thus, 
resiquimod can mimic the immunostimulatory effects of a naturally occurring viral infection.  
 
Antigens in vaccine formulations 
 The other major component of vaccines is the antigen. This perhaps is considered most 
important because it is responsible for the specificity of the immune system response. 
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Prophylactic vaccines most commonly contain a protein or carbohydrate antigen.30 Protein 
antigens, minimal peptide epitopes, and cell lysates are the most commonly used antigens in 
therapeutic vaccines.31 One advantage of whole protein antigens is that they often contain 
multiple antigenic epitopes capable of being recognized by MHCI or MHCII proteins or B 
lymphocyte receptors (BCRs).  As such, they are capable of simultaneously activating both CD8 
and CD4 T cells as well as the humoral arm (antibodies) of the immune system.  
Minimal peptide epitopes activate CD8 when complexed with MHCI and CD4 T cells 
when complexed with MHCII proteins.32 Finally, whole cell lysates are commonly used as the 
antigen source for cancer vaccines. The lysate is derived from cells taken from either the 
individual’s own tumor, called autologous cell lysate vaccines, or from the tumor of another 
unrelated individual with the same type of cancer, called allogeneic cell lysate vaccines.33 As with 
whole protein antigens, which are also present in cell lysates, whole cell lysates are able to 
activate both the cell-mediated and humoral arms of the immune system. An additional advantage 
of lysates is that they contain multiple proteins and other types (i.e. carbohydrate) of antigens.  
Many of which are unique to the tumor as a result of genetic mutations during cancer cell growth. 
This latter type of antigen is referred to as a neoantigen34,35 and has become a promising new 
target for therapeutic vaccines.  
 
Delivery vehicles in vaccines 
A third and critical aspect of a vaccine is the control of the availability of the antigen. The 
use of polymers as vaccine delivery vehicles has evolved to a prominent area of research in the 
last couple of decades. Polymer vehicles can not only act as an adjuvant but also function as 
controlled-release depots and/or as immune cell targeting particles.36  
The use of biodegradable polymers as delivery vehicles is a very promising approach and 
has continued to gain momentum in the drive towards the improved design of next-generation 
vaccines. Poly-(lactic-co-glycolic acid; PLGA) is the most widely used polymer for this 
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application due to its biocompatibility, large body of research, and FDA approval status. 
However, despite the encouraging status of therapeutic vaccines in clinical trials, only a single 
phase I trial involves the use of a polymer-based therapeutic vaccine (clinicaltrials.gov as of 
2/21/13). The apparent disconnect may be a result of the relatively poor understanding of the 
interaction between polymeric biomaterials and the immune system. Although the majority of 
polymer-based vaccines are well designed based on rationale chemical approaches, a clear 
immunologically-guided rationale appears lacking.  
The rationale for polymer-based delivery of vaccines is driven by two main aspects. The 
first is that polymer-based vaccines can be formulated to molecularly mimic pathogenic viruses 
via their ability to undergo phagocytosis and to persist within antigen presenting cells.  This 
should provide a more potent immune response. The second aspect is the depot effect by which 
the polymer provides a persistent source of antigen and adjuvant to the immune system. The 
degradation of a polymer in vivo is largely determined by its backbone chemistry but also 
molecular weight, which is further governed by the monomer composition and distribution of 
monomers within the copolymer backbone. Characterization of these properties is required to 
validate the synthetic strategy employed. The self-assembly behavior of the copolymer in 
aqueous solution can dictate its ability to encapsulate various peptides/drugs as well as modulate 
the release of the loaded compounds from the polymer. Additionally, manipulation of the 
fractional composition of monomers may produce control over the relative size of assembled 
structures in solution. 
The ease of phagocytosis is primarily dependent on formulation of the polymer vehicle 
(encapsulating vaccine components) into appropriately sized particles, often referred to as 
particulate antigens. The optimal size of the particulate antigens for uptake by APCs is generally 
in the range of 50-1000 nm.37,38 Following internalization by APCs, particulate antigens have 
demonstrated the ability to persist within the cytosol, providing for increased and prolonged rates 
of antigen cross-presentation and sustained production of important cytokines including 
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interleukin-2 (IL-2)39 and interferon gamma (IFN-g).40 Shen H et al.41 reported that nanoparticles 
(500 to 1000 nm), generated from a biodegradable polymer, poly-(D,L-lactide-co-glycolide) 
(PLGA), and encapsulating OVA protein, were able to persist within the cytosol for 4 days. This 
represents a significant increase in time available for antigen cross-presentation to occur as 
soluble antigens typically persist for only a couple of hours after uptake. Another report42 
suggests that the particles can become entrapped within the partially acidic endosomal 
environment and thereby promote antigen cross-presentation upon fusion with vesicles 
originating from the endoplasmic reticulum and carrying MHCI proteins. In addition, particulate 
antigens have a demonstrated ability to generate increases in the magnitude, duration, and 
cytotoxicity of antigen-specific CD8 T-cells in vivo. 
The depot effect embodies the concept that a persistent source of antigen/adjuvant to the 
immune system will provide a sustained immune response. The sustainment of the immune 
response will then, theoretically, translate into improved eradication of the diseased cells. This 
strategy serves as the basis behind Freund’s Complete Adjuvant (FCA)43. FCA is composed of 
light mineral oil, mannide monooleate (a surfactant agent), and heat-killed and dried 
mycobacterial cells.44 FCA still remains the most potent antibody-stimulating adjuvant known to 
date. Despite its unmatched adjuvant effect, the use of FCA is not permitted for human use 
because it has been associated with a variety of lesions, including localized injection site lesions 
and diffuse granulomas.45 This led to the development of Incomplete Freund’s Adjuvant (IFA), 
which was first used by Jonus Salk in the 1950s in an attempt to improve influenza vaccines.46 
IFA differs from FCA in that it lacks the killed mycobacterial cells. 47 The removal of the killed 
mycobacterial cells significantly improves the safety profile of the emulsion, which has received 
approval by the Food & Drug Administration for use in humans. 
Both FCA and FIA are prepared by emulsifying an aqueous solution and mannide 
monooleate oil to produce a water-in-oil emulsion. Antigen, buffered in water, is incorporated 
into the aqueous phase of the emulsion. Upon injection, the mixture forms a depot in the 
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extracellular environment and provides for controlled-release of antigen for 3-4 weeks. 
Maintaining the antigen in a single location is reported to prevent exposure to effector cells of the 
immune system. A reaction to the injection can lead to encapsulation of the vaccine with fibrous 
tissue, which limits release of the antigen. The formation of a stable water-in-oil emulsion is a 
critical step in the effectiveness of both adjuvants.  The potential of IFA for use as a single-dose 
vaccinations in underdeveloped countries and to induce persistent, high titer protective antibodies 
has been very promising.  
Interestingly, the adjuvant activity of IFA, without the incorporation of a TLR agonist, 
was traditionally believed to function by three different mechanisms of action; these include 
establishing an antigen depot with slow antigen release, providing a vehicle for antigen transport 
throughout the lymphatic system to immune effector cells, and interacting with antigen-
presenting cells including phagocytes, macrophages, and dendritic cells.48 However, recently, this 
has been questioned. There is a debate as to whether the adjuvant effect of IFA exists solely due 
to the slow release of antigen or there is an intrinsic adjuvant effect of the IFA itself. 
Many polymer-based vaccines have been prepared with the intent to incorporate both of 
the approaches described above.49 Most commonly, biodegradable polymers are used to 
encapsulate, or incorporate by similar means, the vaccine antigen and adjuvant. Studies report 
both the increased uptake of the micro- or nanoparticles by the cells of the immune system and 
also the sustained release of the antigen and adjuvant from the polymer. However, the release 
studies are performed in vitro, and thus the rates of release are dependent solely on diffusive 
release of antigen and adjuvant from the polymer. It is likely that the in vitro biodegradation and 
release kinetics are poor predictors of their in vivo behavior. Often, in vitro time release profiles 
of weeks to months are reported. In vivo, however, the phagocytic cells of the immune system 
take up the entire vaccine particle within hours after injection. Moreover, evidence demonstrating 
the ability of nano- and/or microparticles to persist within the cytosol of the DC for only 4 days, 
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the reported in vitro release rates of antigen and adjuvant are irrelevant to the in vivo 
performance.  
To date, few examples wherein both strategies are effectively used exist. Irvine, et al,50 
compared intranodal versus intramuscular injections of both PLGA nanoparticles and large, ~10 – 
20 µm, microparticles containing fluorescently labeled polyI:C. The authors observed that 24 
hours after injection, the uptake of fluorescently labeled polyI:C by macrophages and DCs in the 
lymph node was increased in the nanoparticles as compared to the microparticles injected 
intranodally, with the percent of cells containing fluorescently labeled polyI:C being 20-25% 
versus 1-2% in the two groups, respectively. The particles injected intramuscularly showed 
minimal uptake, and no difference was observed between groups. At 96 hours post-injection, the 
intranodally injected microparticles continued to provide sustained release of polyI:C into the 
lymph node, translating into prolonged activation of immune cells. The rationale was that the size 
of the microparticles was beyond the limit for uptake by phagocytic immune cells, and the 
sustained release afforded by the PLGA polymer was maintained in vivo. Conversely, the release 
kinetics of adjuvant from nanoparticles failed to be maintained in vivo because of the rapid uptake 
of the particles by the cells of the immune system. Although these experimental observations 
offer a unique look at the potential for combining both advantages of polymer delivery, there 
remains a significant challenge in translating the vaccine to the clinic. 
 
CURRENT STATE OF CANCER VACCINES AND HYPOTHESIS 
Current state of cancer vaccines 
Antigen 
Despite the promising potential of therapeutic vaccines, their development has yet to 
achieve the level of success seen with adaptive cell therapies51 or monoclonal antibodies.52 One 
key reason for this discrepancy is the existing gaps in knowledge as to the magnitude, duration, 
and qualitative nature of immune response required to eliminate cancer cells.  
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It is thought that an effective cancer vaccine must produce large numbers of tumor 
antigen peptide-MHCI-specific CD8 T cells capable of killing tumor cells. As a result, CD8 T 
cells have been the focus of many therapeutic vaccines because of their direct cytotoxic activities 
against target cells. Various modified forms of vaccines (i.e. cell lysates, peptides, proteins) have 
been utilized in an attempt to find the “ideal” vaccine components. Presently, there is great 
interest in the use of minimal peptide epitopes for activation of cytotoxic CD8 T cells against 
cancer cell antigens. However, targeting minimal peptide epitopes has not been shown to 
stimulate a sufficiently powerful immune response to overcome the aggressive nature of cancer 
cells nor their intrinsic ability to escape the cells of the immune system.53,54 In contrast, attacking 
the cancer from a number of angles, i.e. an orchestrated attack from both arms of the immune 
system, has been shown to produce improvements in overall survival in preclinical models of 
GBM55 as well as other cancers.56  
The same has proven true in human trials, as the vast majority of CD8 T cell-targeted 
cancer vaccines have failed to produce an increase in patient survival.57,58 However, this may 
occur because of tumor down-regulation of the relevant protein as a means of avoiding CD8 T 
cell recognition.59 The vast majority of therapeutic vaccines, including polymer-based 
approaches, have failed to account for the important role of helper and effector CD4 T cells60 and 
antibodies.61 Only recently has it been suggested that tumor antigen-specific CD4 T cells are also 
required for effective tumor control.62,63   
 
Delivery systems 
Much work has gone into studying various methods of antigen (and adjuvant) delivery, 
such as dendritic cell vaccines and polymer vehicles, in order to alter timing, to mimic naturally 
occurring infections, and to target specific immune cells. Despite the advances in the chemical 
design of vaccine delivery vehicle, there remains a clear gap in knowledge as to how the rate and 
duration of release of antigen and adjuvant from the vehicle or the uptake of the particulate 
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vaccine affects the magnitude, duration, and/or qualitative nature of the theoretical immune 
response. Thus, although the majority of polymer-based vaccines are well designed based on 
rationale chemical approaches, a clear immunologically-guided rationale is often lacking. 
 
Persistent antigens and exhaustion 
The effect of persistent antigen on the therapeutic functioning of the immune response is 
a fine balance between stimulation and exhaustion. In many cases, high levels of persisting 
antigen, from either vaccination or uncontrolled infections, have been shown to cause the immune 
system to become “exhausted”.64,65 In the case of many chronic infections, high and systemic 
levels of persisting antigen have been shown to cause peptide-MHC-specific T cells to suffer a 
decrease in their cytotoxicity and/or an up-regulation of an immunosuppressive state. The 
interplay of functional efficacy and exhaustion of the immune system has been shown to be a 
product of the magnitude and duration of persistence antigen as well as the qualitative nature of 
the immune response.  
In chronic viral infections, there is an indication of continual progression of immune 
system exhaustion with time, although this is seemingly dependent upon the degree of 
pathogenicity and localization of the disease. In a study of the immune response to HIV66, the 
authors established that clearance of the pathogen resulted in reduced immunity and protection 
from repeat infection, suggesting that in this, and potentially other disease states, sustained 
protection from reinfection may depend on continuous exposure to low levels of antigen.67 
Similarly, the Jenkins’ lab at the U of MN showed that Salmonella enterica infection, which 
persists at low levels within the mesenteric lymph nodes for prolonged periods, sustains the 
number and function of peptide-MHCII-specific memory CD4 T cells. This effect was lost upon 
eradication of the infection with antibiotics or if the infection became systemic. This suggests that 
sources of persistent antigen may be most beneficial when confined to a localized space.68 These 
same findings were true in a murine model of Leishmania major (L. major) infection, where 
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protection from repeat infection (or primary infection following vaccination) was found to 
correlate strongly with the presence of polyfunctional CD4 T cells, independent of the frequency 
of these cells. 
With regards to the qualitative nature of the immune response, antigen-specific CD4 T 
cells have the ability to “rescue” exhausted CD8 T cells during chronic viral infections.69 This 
suggests that CD4 T cells have a vital role in generating and maintaining the quality of the CD8 T 
cell response. Assessment of the CD8 T cell response in the absence of a CD4 T cell epitope fails 
to account for the impact that CD4 T cells have in forming the overall response to vaccination (or 
infection). Therefore, incorporation of a CD4 T cell epitope with a CD8 T cell epitope may 
improve the immune response against difficult targets such as tumors. Taking all of these studies 
together, there is compelling support for the contention that the failure of a vaccine to stimulate a 
“complete” immune response, involving CD4 and CD8 T cells as well as antibodies, adversely 
affected the efficacy and potential clinical translation of therapeutic vaccines.  
To achieve a “complete” immune response, polymer-based vaccines, such as poly (lactic-
co-glycolic acid) or PLGA, have been designed with entire protein antigens incorporated into the 
matrix. This approach has the potential to activate both the humoral (antibody) and cellular (both 
CD8 and CD4 T cell) arms of the adaptive immune response. However, despite the probable 
generation of an antigen-specific CD4 T cell response in these studies, research has been limited 
to the analysis of antibody and/or CD8 T cell response.70,71,72 This is likely due to the widespread, 
commercial availability of tools for studying these responses. In contrast, quality assessments of 
CD4 T cells are limited to a great extent by the lack of quality experimental tools as well as the 
comparatively small number of well-defined CD4 T cell epitopes in cancer.  
 
Hypothesis 
The progress achieved with immunotherapy in other malignancies has failed to be 
realized in GBM. Despite the development of numerous vaccines capable of generating an 
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immune response against tumor antigens, none has yet demonstrated any meaningful advances in 
overall survival. We believe that the disconnect between the anti-tumor immune response and 
tumor regression/survival is in part due to the lack of a well-defined kinetic profile for an 
effective therapeutic immune response to cancer. This disconnect exists in the type, quality, 
quantity and duration of the anti-tumor immune response. Therefore, we attempted to identify a 
relationship between the magnitude and duration of the immune response to a controlled-release 
vaccine and the resulting therapeutic benefit in a mouse model of glioblastoma multiforme.73  
The approach involved the use of a novel, biodegradable and biocompatible semi-solid 
polymer vehicle, poly-(ε-caprolactone)-poly-(ortho ester) [PCL-POE] (figure 2). The novelty of 
this polymer is that the antigen and adjuvant are both readily mixed into the semi-solid at room 
temperature and, upon injection into the extracellular space, a depot forms. When administered 
subcutaneously, the polymer itself is able to persist over a period of 3 to 4 weeks, allowing for a 
slow and continuous release of the antigen and adjuvant into the extracellular space. Thus, the 
role of persistent antigen (and adjuvant) on the immune response and on overall survival in a 
model of GBM could be studied. We hypothesized that the slow release of antigen and adjuvant 
from the novel PCL-POE polymer would extend the presence of effector T cells and antibodies in 
the lymphatic system and tissues after injection, thereby resulting in an increase in overall 
survival in our mouse model of glioblastoma multiforme. To confirm this hypothesis, we tested 
the following specific aims: 
1. Establish the ability of the PCL-POE polymer to provide sustained release of both 
antigen and adjuvant in vitro 
2. Establish a correlation between persistent release of antigen and adjuvant from the 
PCL-POE polymer and the extended duration of the innate and adaptive immune 
responses 
3. Establish the ability of the extended duration of the innate and adaptive immune 
responses to increase overall survival in a mouse model of glioma 
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MATERIALS AND METHODS 
In vitro release studies 
 The in vitro release of OVA protein and RES from the PCL-POE semi-solid polymer was 
measured as follows. First, 1000 µg of OVA and 200 µg of RES were mixed with 200 µl of the 
polymer and placed into 10 mL of PBS in a 50 mL conical tube. The sample was then incubated 
at 37°C while rotating at 200 revolutions per minute (RPMs). At each indicated time point, 2 mL 
of supernatant was collected and replaced with 8 mL of fresh PBS. Mini dialysis centrifuge tubes 
with a MW cut-off of 3500 kDa were used to separate the OVA protein from RES. Both 
compounds are completely soluble in 100% methanol, which used as the dialysate fluid. The 
dialysis fluid was replaced at 4, 8 and 18-24 hrs. The dialysate was collected and the OVA 
protein within the dialysis tubing was collected by repeated rinsing with sterile water. All samples 
were dried to a powder form by a combination of rotary evaporation and speed vacuuming. The 
amount of OVA contained in each sample was quantified using the bicinchoninic acid (BCA) 
Protein Assay Kit (Thermo Scientific Pierce). The amount of RES in each sample was measured 
using liquid chromatography-mass spectrometry (LC-MS/MS).  
 We followed the manufacturer’s protocol for the Microplate Procedure. The technique 
allows for use of a smaller volume (10-25µL) of protein sample with sensitive detection. 
Ovalbumin was used as the standard. Concentrations from 5 µg/mL to 500 µg/mL were used to 
create the standard curve. The r-squared value for the standard curve was 0.993. Each sample was 
suspended in 250 µL of sterile water, and 25 µL of each standard or sample was added to a single 
well of a 96 well ELISA plate (Thermo Scientific Pierce), and 200 µL of the blue colorimetric 
reagent.  The samples were then incubated at 37° for 30 minutes. The reaction involved the well-
known reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the highly sensitive and 
selective colorimetric detection of the cuprous cation (Cu1+) by bicinchoninic acid. The second 
reaction results in an intensely purple-colored reaction product, the absorbance of which is 
measured at 562 nm using a plate reader. All samples and standards were run in triplicate.  
25 
 
The concentration of resiquimod was determined using a specific and sensitive LC-
MS/MS assay. RES standards were diluted in methanol, dried under a gentle stream of nitrogen, 
and reconstituted in 100 µl mobile phase. RES samples were diluted in 500 µl mobile phase. The 
sample was then diluted further to obtain a concentration in the linear range of the LC-MS/MS 
assay (a 1:400 dilution). Following reconstitution in mobile phase, the standards and samples 
were vortexed and transferred to auto sampler vials. A 5 µl sample was injected onto a Zorbax 
Eclipse SB-C18 column (4.6 x 75 mm, 3.5 µm particle size; Agilent Technologies, Santa Clara, 
CA). The aqueous mobile phase was 25 mM ammonium formate with 0.1% formic acid, and the 
organic mobile phase was acetonitrile (75:25; v/v) and was delivered at a flow rate of 0.5 ml/min 
total with a total run-time of 8 min. The ionization was conducted in positive mode, and the m/z 
transition was 196.295 → 197.795. The retention time of RES was 4.47 minutes. The assay was 
sensitive and linear over a range of 1-500 ng/ml, with the coefficient of variation being less than 
20% over the entire range. 
 
Flow cytometry 
All antibodies, except where indicated, were obtained from eBioscience. Phycoerythrin 
(PE)-conjugated Kb-OVA peptide–MHC multimer staining was performed with dextramer 
(Immudex).  
Single cell suspensions (4–5 × 105 cells in 100 µl of whole blood) were stained for 30 
minutes at room temperature with 100 ng/µL PE-conjugated Kb-OVA dextramer. For 
identification of surface T cell surface markers, the samples were stained for 45 minutes on ice 
with the following antibodies; perCP-Cy5.5-conjugated anti-mouse CD8α (clone 53-6.7), Alexa 
Fluor 700-conjugated anti-mouse CD44 (clone IM7), allophycocyanin (APC)-e780-conjugated 
anti-mouse CD3ε (clone 17A2), APC-conjugated anti-mouse CD4, (Clone GK1.5), fluorescein 
isothiocyanate (FITC)-conjugated anti-mouse PD-1 (CD279) (clone J43), Pacific Blue-
conjugated anti-mouse LAG-3 (CD223) (clone C9B7W), and KLRG1 PE-Cy7-conjugated anti-
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mouse (clone 2F1). In experiments designed to detect nuclear proteins the cells were surface 
stained with some of the aforementioned antibodies, then treated with Foxp3 
Fixation/Permeabilization Concentrate and Diluent (eBioscience), and stained for 1 hour on ice 
with an Alexa Fluor 647-conjugated anti-mouse Ki67 (clone SolA15) antibody. After each stain, 
cell samples were washed twice with PBS prior to analysis. Appropriate isotype controls were 
used. 
For dendritic cell maturation assays, single cell suspension of the lymph node were 
stained on ice with the following antibodies for identification of surface markers; FITC-
conjugated anti-mouse CD11c (clone N418), PE-Cy7-conjugated anti-mouse MHCII (clone 
M5/114.15.2), APC-conjugated anti-mouse CD86 (clone GL1), and Pacific Blue-conjugated anti-
mouse CD80 (clone 16-10A1; BioLegend). Samples were analyzed on a BD FACSCanto II flow 
cytometer. Data were analyzed with FlowJo software (TreeStar). 
  
Cell lines and culture  
All GL261 cell lines were stably transfected with Luciferase maintained by selection with 
1mg/mL puromycin. The GL261 cell line grown in 5 % oxygen was maintained as neurosphere 
cultures in DMEM/F12 (1:1) media supplemented with L-glutamine, sodium bicarbonate, 
penicillin/streptomycin (100 U/ml), B27 and N2 supplements, 0.1-mg/ml normocin, and EGF-F 
and FGF-F cytokines. Cytokines were replenished twice per week. Cells were maintained at 5 % 
oxygen for a minimum of two weeks prior to use. The GL261 cell line grown in 20 % oxygen 
was maintained in Dulbecco’s Modification of Eagle’s Medium (DMEM) supplemented with 
10% with fetal bovine serum and were maintained by selection with 1 mg/mL G418. All culture 
media contained 100 U/mL penicillin/streptomycin and 0.1mg/mL normocin.  
 
Mouse models  
Mouse experiments were performed in accordance with University of Minnesota Animal 
27 
 
Care and Use Committee guidelines. C57BL/6 (B6) mice and C57BL/6-Tg(TcraTcrb)1100Mjb/J 
(OT-I) mice were purchased from the Jackson Laboratory and were maintained in a specific 
pathogen-free facility. For all experiments, the age of the mice was between six and eight weeks.   
For studies of the immune response to persistent antigen, we used C57BL/6-
Tg(TcraTcrb)1100Mjb/J (OT-I) mice for our positive control mice. These transgenic mice have 
100% of their T cell receptors (TCRs) specific for the SIINFEKL:2-Kb peptide:MHCI complex. 
Thus, we are able to utilize non-transgenic mice of the same genetic background to study their 
response to OVA protein vaccine. 
For our survival studies, we used whole cell lysates grown in 5% O2 as our vaccine 
antigen, because the GBM tumor model was grown from a mouse glioma cell line, GL261, which 
does not express the OVA antigen. As such, it better mimics the natural growth of a GBM than an 
OVA-expressing GL261 cell line. For orthotopic glioma models, single cell suspensions of a 
glioma cell line, GL261, was suspended in PBS and treated with 1 µL On-column DNase (Sigma) 
per 100 mL of cells. A maximum of 1 µL of cell suspension was inoculated in the right striatum, 
2.5 mm lateral and 0.5 mm anterior of bregma, and 3 mm deep from the cortical surface of the 
brain. The number of cells used in the inoculation was 15,000 GL261 cells in a 1 µL injection. 
Tumor development and growth were assessed routinely by bioluminescent imaging. Per 
protocol, glioma bearing mice were euthanized, when they became symptomatic.  
 
Vaccine Preparation 
For the polymer vaccinations, 800 mg of whole ovalbumin protein (Anaspec) and 200 mg 
of resiquimod (prepared by the laboratory of Dr. Dave Ferguson, Department of Medicinal 
Chemistry, University of Minnesota) were placed into 100 µL of PCL-POE, and a uniform 
solution was obtained by stirring for 2 minutes.  All vaccination samples were used within one 
hour of preparation. Control (solubilized) vaccinations were diluted in PBS to a final 
concentration of 200 µg Ovalbumin and 50 µg resiquimod per 100 µL of PBS.  For control 
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vaccinations, resiquimod was solubilized in 2% DMSO/PBS. Ovalbumin was diluted in PBS.  
Lysate vaccines were prepared from GL261 cultures grown in 5% oxygen. Cells were 
collected, counted, and re-suspended at a concentration of 10 million tumor cells per 1 mL PBS. 
Each sample was treated with liquid N2 for 30 seconds followed by lyophilization for 48 hours 
using (machine, company) and then stored at -80°C. On the day of vaccination, cell lysate 
powders were either re-suspended along with resiquimod at a final concentration of 2.5 million 
tumor cells and 50 µg resiquimod per 100 µL PBS (for soluble vaccines) or mixed with 
resiquimod into 100 uL of PCL-POE at final concentrations of 10 million tumor cells and 200 µg 
resiquimod per 100 µL polymer. Polymer vaccines were mixed for 2 minutes and were used 
within one hour of preparation. Just prior to each individual vaccination, the preparation was 
again mixed using a double-syringe luer-lock system. 
 
Vaccination protocol 
 Mice were vaccinated with either 100 µL of polymer or soluble (control) vaccine. All 
vaccinations were administered as subcutaneous injections at the base of the left hind leg near the 
inguinal lymph node. For OVA-containing vaccine, soluble vaccines were administered once 
daily for four consecutive days. Polymer vaccines were given as a single dose. All vaccines were 
prepared at the time of vaccination. For cell lysate experiments, soluble vaccinations were given 
once weekly (beginning 7 days post-inoculation) for 4 consecutive weeks. For both sets of 
experiments, polymer vaccines were given either once (day 7 post-inoculation) or twice (days 7 
and 28 post-inoculation).  
 
Dendritic Cell Maturation Assay 
 For analysis of DC maturation, mice were sacrificed at one and two weeks post-
vaccination. Draining lymph nodes were harvested and single cell suspensions were prepared. 
Single cell suspensions were resuspended to a concentration of 4–5 × 105 cells per 100 µl of PBS. 
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Samples were stained with surface antibodies against CD11c, CD80, CD86, and MHCII in the 
dark on ice for 45 minutes. Samples were then washed twice with PBS and suspended in 100 µL 
of PBS and analyzed. 
 
ELISA  
Detection of plasma anti-OVA antibodies was performed with a standard enzyme-linked 
immunosorbent assay (ELISA). Whole Ovalbumin protein (Fisher) was plated at 0.5 µg/ml in 
PBS (100 µL/well) in 96-well flat bottom plates (company) and incubated overnight at 4ºC in the 
dark. Each well was washed with 2% fraction V BSA/PBS (Sigma Aldrich) (100 µL/well) for 60 
min at room temperature in the dark. Wells were then washed one time with 0.5% fraction V 
BSA/PBS (200 µL/well). Plasma samples were thawed and added to each well at dilutions of 
1:10, 1:100, or 1:1000 in PBS (100 µL/well) and incubated for 2 hrs at room temperature in the 
dark. Wells were then washed three times with 0.5% fraction V BSA/PBS (200 uL/well) and one 
time with PBS (200 uL/well). Next, 100 µL of a 1:2500 goat anti-mouse IgG (H + L) polyclonal 
alkaline phosphatase-conjugated secondary antibody (Thermo Scientific Pierce) was added to 
each well, and the plate was incubated for 1 hour at room temperature in the dark. Wells were 
then washed three times with 0.5% fraction V BSA/PBS (200 uL/well) and one time with PBS 
(200 uL/well). Thereafter, 100 µL of a 1 mg/mL p-nitrophenyl phosphate/diethanolamine buffer 
solution (Thermo Scientific) was added to each well. The reaction was allowed to proceed at 
room temperature in the dark for 20 min, and the absorbance was read at 405 nm using a plate 
reader. 
 
Model protein antigens 
For our studies of the immune response to the controlled release of vaccine components 
by PCL-POE polymer, we utilized a model protein antigen, chicken ovalbumin (OVA). We chose 
OVA as our model antigen because reagents exist that allowed us to track the CD8 T cell 
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response specific for the predominant CD8 epitope, SIINFEKL, contained within the OVA 
protein. The reagent was a dextramer of Kb:SIINFEKL (Immudex). Use of a multimeric complex 
of a specific peptide:MHC molecule results in increased reliability and improved detection of an 
antigen specific T cell population.  
 
Measurement of the OVA-specific CD8 T cell response 
For our studies, identification of SIINFEKL (OVA)-specific CD8 T cells was performed 
using whole mouse blood. On the indicated day post-vaccination, either 100 µL of blood was 
collected via the periorbital vein or the mouse was sacrificed and secondary lymphoid organs 
removed for cell harvesting. The latter method was used for repeat immune monitoring because a 
greater number of total immune cells could be collected from the secondary organs relative to that 
in 100 µL of blood. Thus, improved accuracy in measurement of the cells of interest was 
achieved. For periorbital blood collection, mice were anesthetized with continuous flow of 0.4% 
isoflurane and a single drop of local anesthetic, proparacaine hydrochloride 0.5 %, was placed onto 
the site of collection. The respiration and heart rates of the mice were monitored during 
anesthesia. Sterile 100 µl capillary tubes were used for collection, and the collected blood was 
placed into conical tubes containing heparin. Mice were treated with an antibiotic ointment 
(Triple Antibiotic Ointment®; Boynton Pharmacy) at the collection site and aroused by removal 
from isoflurane. Mice were monitored for a minimum of 1 hour after wakening and until normal 
feeding and activity resumed. After collection of immune cells by either method, samples were 
treated with 10 µL of PE-conjugated Kb:SIINFEKL dextramer (Immudex) per 1,000,000 total 
cells. Samples were vortexed and incubated at room temperature in the dark for 30 minutes. The 
samples were stained with fluorescently-labeled antibodies for CD8, CD3 and other markers of 
interest at a 1:100 v/v concentration, and incubated on ice for 45 minutes in the dark. After 
staining, samples were washed to remove unbound antibody, centrifuged at 1000 x g for 5 
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minutes and the supernatant removed by aspiration. Samples were re-suspended with 100 µL of 
PBS and the percentage of OVA-specific CD8 T cells was analyzed by flow cytometry. 
 
Measurement of non-specific CD8 and CD4 T cell responses 
 For identification of rapidly dividing CD8 or CD4 T cells, which served as an indicator of 
response to treatment after treatment with lysate antigen, samples were stained after treatment 
with lysate antigen with anti-mouse antibodies against CD8α, CD3ε, and CD44 in the dark at 4ºC 
for 45 minutes, followed by washing with PBS. Ki67 expression marker was used as the 
intracellular marker for identification of proliferating cells.  Ki67 was detected by first 
permeabilizing and then fixing the cells with a FoxP3 Cell Permeabilization Buffer Kit 
(eBioscience). Samples were suspended in 400 µL of a 1x concentration of the permeabilization 
buffer and incubated at 4ºC for 1 hour in the dark. Samples were then washed twice with PBS and 
stained with a 1:100 concentration of anti-mouse Ki67 in the permeabilization buffer for 1 hour at 
4ºC in the dark. Samples were then washed twice with PBS and resuspended in 100 µL of PBS 
and analyzed. 
 
Statistical analysis 
Statistical analysis and curve fitting were performed using Prism software (Graphpad). 
Significance analysis was performed with Student’s unpaired t-test.  For the Kaplan-Meier 
survival curves, the log rank test was used.  The significance of the results are expressed with the 
p values, using the following notation: *:p<0.05; **:p<0.01; ***: p<.001.  
 
32 
 
RESULTS AND DISCUSSION 
The ultimate goal of this research was to identify an effective vaccine for the treatment of 
glioblastoma multiforme. The approach involved the use of a polymer vehicle that provided a 
slow, continuous release of antigen and adjuvant. In addressing this goal, a careful and systematic 
approach was followed, where several aspects of the immunological response were investigated. 
This included in vitro release studies to characterize the release of the model protein antigen, 
ovalbumin (OVA), and the immunostimulant drug, resiquimod (RES), from the polymer.  With 
vaccine administration, the time course of the biological response was assessed by examination of 
dendritic cell maturation via their up-regulation of MHC-II, CD80, and CD86 levels, antigen-
specific IgG and IgM antibodies, tumor lysate-specific CD8 and CD4 T cells, and ultimately the 
effect on cancer progression and survival in the mouse animal model. 
 
Time-release profile of antigen and adjuvant from PCL-POE polymer in vitro 
The in vitro release of 1000 µg OVA and 250 µg resiquimod from the PCL-POE polymer 
was examined. In these studies, the polymer is insoluble and has a higher density than water, so it 
remained as a semisolid mass at the bottom of the centrifuge tube in the release study. In Figure 
3a, the cumulative percent release of Ovalbumin (OVA) is given as a function of time over a 
period of 28 days.  As can be seen, the cumulative percent release initially increased in a linear 
manner for the first four days where just less than 20 % (ca 200 µg) of OVA was released.  
Thereafter, the release rate progressively decreased yielding a curvilinear relationship reaching 
nearly 50 % release at 28 days. In Figure 3b, the corresponding results for resiquimod are given.  
As with OVA, the release was linear for the first four days with about 60% (ca 150 µg) release 
and then slowed over the remainder of the experiment.  Nearly 100% was released by the 28th 
day.    
Comparing the release of vaccines components from the PCL-POE polymer showed that 
while approximately sixty percent of Ovalbumin protein was released over 4 weeks, release of 
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Resiquimod, a much smaller and hydrophobic molecule, was much more complete in the same 
time frame. Both showed a more rapid linear release rate over the first 4 days. This burst release 
was followed by a slower, apparently linear release for the remainder of the study. The similar 
time course of OVA and RES from the polymer is suggestive of a comparable mechanism in the 
control of the release. Important for the immunological response, the burst release in the initial 
phase corresponds to a time profile that closely approximates the time over which pathogens are 
rapidly replicating during an acute infection or that of a rapidly growing tumor. The slower phase 
of release closely resembles that of a chronic infection or a slow growing tumor.   
While the release profile from polymer vehicles is readily measured in vitro, 
experimental difficulties have prevented the accurate, quantitative measurement of the release in 
vivo. In general with polymer vehicles, the in vitro release kinetics is often a poor predictor of in 
vivo behavior. For a nano- or microparticulate polymer vaccine, the in vitro release rates may be 
significantly different from that observed in vivo as a result of phagocytosis and intracellular 
digestion of the polymer by dendritic cells (DCs), macrophages and other non-professional APCs. 
Given the presence of widely expressed esterases, PCL-POE degradation will occur in vivo but 
not during the in vitro release measurement.  Thus, with the differences in the degradation rate of 
the polymer, we would expect that the rate of release from the PCL-POE polymer would be more 
rapid in vivo because the release of vaccine components will be a product of both polymer 
degradation and molecule diffusion within the polymer.  
The advantage of the novel PCL-POE semi-solid polymer used in this research is that 
upon injection it approaches a solid state. As such, it is able to persist in vivo for a much longer 
time than polymer particles, because cells of the immune system are unable to phagocytose the 
intact semi-solid. This is analogous to the injection of Freund’s oil-in-water emulsion that results 
in an initial reaction at the injection site, which ultimately led to encapsulation of the injected 
material within fibrous support tissue. By sheltering the antigen in a single location, the polymer 
depot is able to prevent exposure to effector cells of the immune system and thereby allow for 
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prolonged release of antigen and adjuvant with a rate determined solely by the rate of release 
from the polymer. Support for this assertion was obtained by visual inspection of the polymer 
mass in mice following injection.  Here, we were able to substantiate that the polymer remained 
visible at 3-4 weeks reflective of the slow degradation in vivo (data not shown). Although this 
confirmed that the polymer itself persisted for a defined period of time in vivo, additional release 
coincident with polymer degradation would alter the kinetics of antigen and adjuvant release 
relative to that observed in vitro. Nevertheless, the similarity in the time course for each 
component would be expected to remain the same despite the additional release occurring with 
polymer degradation.   
Guided by the results from the in vitro release study, the immunological response was 
then assessed. In this study, OVA antigen was incorporated into PCL-POE with either of two 
adjuvants, RES, or the established T cell adjuvant, polyinositic-polycytidylic acid (polyI:C). 
These two different formulations were then injected as a single subcutaneous injection. As a 
positive control, the two different antigen/adjuvant combinations were also suspended in PBS and 
injected as four consecutive daily boluses (figure 4). The immunological response was evaluated 
by measuring the percentage of OVA-specific CD8 T cells in the blood over time by flow 
cytometry. 
The results are given in Figures 5a, b, and c, which provide the percent of OVA-specific 
CD8 T cells measured in mice as a function of time. In these Figures, the dashed line at about 
0.5% represents the mean percent of naive OVA-specific CD8 T cells in unvaccinated B6 mice.  
Figure 5a provides the data for OVA+polyI:C in PBS given subcutaneously as four 
repetitive once daily bolus injections and OVA+polyI:C in PCL-POE given as a single 
subcutaneous injection. The majority of mice receiving OVA+polyI:C as repetitive injections 
achieved a peak in percent OVA-specific CD8 T cells on day 7 as expected, with values ranging 
from about 1.7 to 7 %. This was followed by the typical contraction and then maintenance phase 
over the next three months. In mice vaccinated with OVA+polyI:C in PCL-POE polymer, the 
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peak OVA-specific CD8 T cell response occurred between days 7 and 21 for the individual mice, 
with the percentage of OVA-specific CD8 T cells ranging from 1 to 3 %. While the peak percent 
of OVA-specific CD8 T cells in the group of mice vaccinated with polymer was significantly 
lower than mice receiving repetitive injections, there was no increase in the duration of OVA-
specific CD8 T cells in the blood in this group. The appreciable variability in the response 
precluded the ability to detect any statistical difference in the peak response, during the 
contraction phase (rate of decline) or in the maintenance phase among these treatment groups.   
In Figure 5b, the results are provided for the formulations: OVA+RES in PBS 
administered subcutaneously as four repetitive once daily doses as well as OVA+RES in PCL-
POE administered as a single subcutaneous injection. The total amount of OVA and RES was 
equivalent in these groups.  As can be seen in the figure, the observed time course when RES was 
incorporated into the polymer was atypical. Specifically, the peak OVA-specific CD8 T cell 
response was lower on day seven, but the percentage of OVA-specific CD8 T cells in the blood 
stream remained elevated for a longer period in comparison to the group receiving four repetitive 
daily boluses of vaccine with the same (RES) adjuvant. In one case, the CD8-T cell response 
continued to increase and reached about 7 % at the last time point monitored in this experiment. 
Approximately half of the mice receiving OVA+RES in PCL-POE polymer achieved a peak in 
percent OVA-specific CD8 T cells ranging from approximately 1 to 5 %. The time of the peak 
response in these mice ranged from day 7 to 30 post-vaccination. The other half of mice receiving 
polymer vaccinations did not achieve an OVA-specific CD8 T cell response beyond that of 
saline-treated mice. In mice vaccinated with OVA+RES in PBS given as repetitive injections, 
only a single mouse achieved a 1.4 % of OVA-specific CD8 T cells, which was above that of 
saline treated mice. 
In Figure 5c, the OVA-specific CD8 T cell response of PCL-POE polymer plus OVA 
with RES is compared to polyI:C. Two differences are apparent from the time profiles. First, the 
group of mice vaccinated with polyI:C developed an OVA-specific CD8 T cell response more 
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typical of an acute exposure to antigen.  This is characterized by a distinct peak early in the 
response and followed by a rapid contraction phase to near baseline percents of OVA-specific 
CD8 T cells in the blood. In contrast, the group receiving resiquimod in the PCL-POE+OVA 
stimulated the activation and maintenance of OVA-specific CD8 T cells for up to two to three 
months. Moreover, the peak response occurred as late as 1 month post-vaccination and in one 
case continuing to increase to 7 % at 3 months post-vaccination, the last time point measured in 
this study. 
To interpret this data, both the kinetics of an immune response to an acute infection 
(bolus dosing) as well as the physicochemical properties of each adjuvant were considered. 
Resiquimod is a small molecule drug that is an analogue of the nucleotide base guanine. It has a 
molecular weight of ~350 kDa, is fairly hydrophobic with an octanol/water partition coefficient 
of nearly 20 (log P=1.3) and is completely insoluble in non-acidic aqueous solutions. In contrast, 
polyI:C is nucleotide polymer of the nucleotide base, cytidylic acid, and the base precursor, 
ionositic acid. The molecule is quite large and polydisperse, with the number of bases in the chain 
ranging from 2000 to 8000 pairs. It is also quite hydrophilic with a high aqueous solubility. 
Because the immunological response of OVA-specific CD8 T cells is directly related to the time 
course of the concentration of these agents, it would appear that the greater hydrophobicity of 
RES relative to polyI:C is an important factor for the initial delay in the peak as well as the 
prolonged, enhanced immunological response.    
 
Measuring the Immune Response to Vaccination 
In considering the observed immune response to the controlled release of vaccine antigen 
and adjuvant by the novel PCL-POE polymer, it is important to examine the properties of the 
model protein antigen, chicken ovalbumin (OVA), in more detail. OVA was chosen, because 
reagents are readily available that allow tracking of the CD8 T cell response specific for the 
predominant CD8 epitope, SIINFEKL, contained within the OVA protein. This reagent consists 
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of a multimer of biotin-conjugated MHCI molecules specific for SIINFEKL. The SIINFEKL 
peptide is loaded into the MHCI protein, and the monomer units are bound together by 
conjugation to a streptavidin core (Figure 6). The purpose of having a multimer is that T cells 
rarely are specific for a single peptide:MHC complex. That is, perhaps as little as 0.1% of the 
cells in the blood of a typical B6 mouse are specific for any given peptide:MHC complex.74 With 
a complete expansion of these antigen-specific T cells by vaccination, characterized by 
approximately 11 doubling events over a 6 to 7 day period, this number could increase to between 
20,000 and 200,000+ cells. Despite such a large expansion, the relative percentage of these cells 
in the blood remains low due to dilution and the localization of T cells to the secondary lymphoid 
organs. For these reasons, detection of a population of T cells by a monomer peptide:MHC 
complex has proven difficult and unreliable (REF). Therefore, use of a multimeric complex of a 
specific peptide:MHC molecule results in increased reliability and improved detection of an 
antigen specific T cell population.  
 
PCL-POE/OVA/RES vaccine-induced maturation of dendritic cells 
Dendritic cells (DCs) are specialized antigen presenting cells (cf Figure 1). They circulate 
within the skin and extracellular spaces of the body. In their immature state, they specialize in 
phagocytosis, continuously sampling the surrounding environment for the presence of foreign 
antigens. Dendritic cells undergo maturation and activation by exposure to microbial agents or 
inflammatory mediators (i.e. adjuvants), marked by their increased expression of major 
histocompatibility complex (MHC) molecules and co-stimulatory molecules such as CD80 and 
CD86. Upon phagocytosis or pinocytosis of a foreign body or antigen, the antigen enters into 
either the endolysosomal (phagocytosis) or cytosolic (pinocytosis) compartments. In both cases, 
the foreign protein antigen is digested by protease enzymes, and peptide epitopes are loaded onto 
either an MHCII or MHCI molecule, respectively. Dendritic cells are often referred to as 
professional antigen presenting cells, because they have the unique ability to transfer digested 
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proteins and peptides that have entered via the endosomal pathway into the cytosol for loading 
onto MHCI molecules. This is an important pathway when the antigen is a whole protein (i.e. 
Ovalbumin) because whole proteins contain both CD4 and CD8 epitopes, requiring loading onto 
MHCII and MHCI molecules, respectively. The DC, now in a mature state, presents the 
peptide:MHC complex on its surface, along with co-stimulatory molecules, and is primed to 
interact with and activate antigen-specific CD4 or CD8 T cells. As described earlier, the T cells 
continuously re-circulate throughout the secondary lymphoid organs in search of their cognate 
antigen. The primed DC simultaneously scans the paracortical (T cell) area of a lymph node in 
search of T cells with T cell receptors specific for the presented peptide:MHC complex. Upon 
interaction with the DC, the naïve antigen-specific T cell is activated to proliferate and develop 
into an antigen-specific effector T cell. 
 Evidence of the intrinsic ability of various polymer vehicles to activate the innate 
immune response, especially dendritic cells, has been well documented in the literature.75, 76 
Based on these considerations, the next set of experiments was carried out to assess the innate 
immune response of OVA/RES in the PCL-POE polymer system. Mice were vaccinated (a) with 
OVA antigen and resiquimod in the PCL-POE polymer administered as a single subcutaneous 
injection, (b) with OVA and resiquimod in PBS given subcutaneously and (c) repetitively as four 
daily bolus injections (positive control), or (d) with a single injection of PCL-POE polymer alone 
(figure 7). The innate immune response was evaluated by measuring the expression of the 
markers of dendritic cell maturation, MHCII, CD80, and CD86. At each time point, mice were 
sacrificed, their lymph nodes harvested, and dendritic cells were identified by expression of 
CD11c.  
The results are given for a single mouse that was representative of the average response 
of each group, and Figure 8 depicts the percentage of dendritic cells expressing MHCII, CD80, 
and CD86 on days 7 and 14. On day 7 post-vaccination, MHCII expression was increased in all 
treatment groups relative to the saline (negative) control group. In the group of mice vaccinated 
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with saline, MHCII was expressed on approximately 7 % of dendritic cells, while in the three 
treatment groups; MHCII was expressed on 32 to 44 % of the dendritic cells. All three groups had 
statistically significant greater expression of MHCII as compared to saline treated mice (p < 
0.05). The pair-wise difference between treatment groups was not statistically significant.  
CD86 expression followed a similar pattern as MHCII on day 7. Mice vaccinated with 
saline expressed CD86 on 15 % of dendritic cells, while mice in the three treatment groups 
expressed CD86 on 32 to 41 % of cells. There was no significant difference between any of the 
groups in the percent expression of CD80 on dendritic cells. There was, however, a small, clear 
population in the PCL-POE polymer only group that showed an increased expression of CD80, 
with 28 % of DCs expressing CD80 as compared to 20 % in the saline treated group. 
On day 14, the percentage of dendritic cells expressing MHCII was still somewhat higher 
in the groups receiving four repetitive boluses of OVA and resiquimod in PBS (positive control) 
and PCL-POE polymer alone. The percent of DCs expressing MHCII in these groups was 21.9 
and 22.8 %, respectively, compared to 17 % in the group receiving saline. The group of mice 
receiving OVA and resiquimod in the PCL-POE polymer, as a single subcutaneous dose, 
continued to display a higher percent of DCs expressing MHCII, which was at 31.2 %. This 
difference was a statistically significant (p < 0.05) relative to all other treatment groups. The 
percentage of DCs expressing CD86 remained greater in mice receiving OVA and resiquimod in 
PCL-POE polymer and PCL-POE polymer alone, both at approximately 30 %, while the group of 
mice receiving four repetitive boluses of OVA and resiquimod in PBS had only 20 % of DCs 
expressing CD86, which was equivalent to that seen in the saline control group. By day 14, 
expression of CD80 by DCs had returned to near baseline levels in all groups, although there 
remained a small but distinct population of DCs in the group of mice vaccinated with OVA and 
resiquimod in PCL-POE polymer that still had an elevated expression, but the difference was not 
significant. 
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The ability of the PCL-POE/OVA/RES vaccine to stimulate prolonged dendritic cell 
maturation is significant, because it is the first step required for activation of a prolonged T cell 
response. The maturation of the DCs essentially acts as the rate-determining step for the initial 
activation of antigen-specific naïve T cells. Of further interest was the finding that, in mice 
receiving polymer alone, there was also a prolonged period of DC maturation. This indicates that 
the polymer itself is being recognized by the innate immune system (DCs, macrophages, 
neutrophils) as foreign, resulting in an adjuvant-like response to the polymer. The intrinsic 
adjuvant activity of the PCL-POE polymer is not unique, since other polymers also demonstrated 
with effect when used as a vaccine vehicle.77,78 
 
Generation of OVA-specific Antibodies in Response to Vaccination with OVA and 
Resiquimod in PCL-POE Polymer  
 
Long-term antibody production is one of the hallmarks of effective vaccination and is an 
important characteristic of immunological memory.79 There have been many mechanisms 
proposed to explain the phenomenon of long-term antibody production and maintenance 
following infection or vaccination. The phenomenon can arise from low level, persistent exposure 
to antigen (i.e. a low-grade chronic infection) or from multiple and repeated exposures to 
antigen.80 Both have the common requirement of continual stimulation of antigen-specific 
memory B cells to proliferate and differentiate into antibody-secreting plasma cells.  Based on the 
in vitro release profile with the caveat in extrapolating the data, it seemed reasonable to expect 
that low levels of OVA and RES would persist in vivo following the initial burst release.  If true, 
then the exposure to these antigens would resemble that seen with many chronic infections. 
Maintaining persistent antigen levels is important for the B cell and antibody responses as evident 
in the work of Murphy and Ohlfest, et al81, in which the presence of plasma cells along with IgG 
were observed in the brain of vaccinated mice with established gliomas. Thus, the next set of 
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experiments addressed the impact of vaccination with the PCL-POE/OVA/RES vaccine on the 
persistence of antibody production and maintenance in the blood stream. 
The anti-tumor antibody response was evaluated by measuring the anti-OVA IgG and 
IgM levels following vaccination. In this study (Fig. 9), mice were vaccinated with (a) OVA 
antigen and resiquimod in the PCL-POE polymer administered as a single subcutaneous injection, 
(b) OVA antigen alone in the PCL-POE polymer administered as a single subcutaneous injection, 
(c) OVA and resiquimod in PBS given subcutaneously and (d) repetitively as four consecutive 
daily bolus injections (positive control), or (e) saline. The anti-OVA IgG and IgM antibody levels 
measured using an enzyme-linked immunosorbent assay (ELISA).  At each time point, plasma 
was obtained from whole blood collection in heparinized conical tubes. The samples were run in 
triplicate and an average result was recorded for each individual mice. The results of this study 
are shown in Figure 10, where the mean and standard error of the mean (SEM) of each treatment 
group are shown.  
Mice treated with OVA and resiquimod in PCL-POE polymer by single subcutaneous 
injection developed an anti-OVA IgG and IgM antibody response that was markedly increased 
over that of any other treatment group. The antibody response peaked at approximately five 
weeks (day 34), although as early as day 20.  It remained elevated at relatively high levels for a 
period of two to three months before undergoing the contraction phase. The increase in anti-OVA 
antibodies in this group was statistically significant at each time point measured from day 20 and 
throughout the remaining time points. The antibody response for 250 days post-vaccination was 
measured, and mice treated with OVA and resiquimod in PCL-POE polymer had a statistically 
significantly higher maintenance level of anti-OVA antibodies compared to all other treatment 
groups.  
 These results are very encouraging in demonstrating that the PCL-POE system results in 
the presence of persistent antigen levels as reflected in the B cell and antibody response.  
Additional experiments are needed to determine the effect of the rate and duration of exposure to 
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persistent antigen on the rate of conversion of naïve antigen-specific B cells into memory B cells. 
Such studies will provide clarification of the effect of persistent vaccine antigen on the kinetics of 
this physiological process. In addition, studies of the rate of change of antibody affinity with time 
would allow for further understanding how persistent vaccine antigen alters the relative portions 
of antigen-specific naïve B cells that differentiate among the three different B cell effector 
pathways. 
 
OVA-specific CD8 T-cell response to Vaccination with OVA and Resiquimod in PCL-POE 
Polymer  
 
 To study the effects of sustained release of OVA on the T-cell mediated arm of the 
immune system, the percent of OVA-specific CD8 T cells was measured at specified time points 
over a four month period in a non-tumor vaccination model (Fig 9). Mice received (a) a single 
dose of OVA and resiquimod in PCL-POE polymer, (b) a single dose of OVA alone in PCL-POE 
polymer, or (c) four consecutive daily doses of OVA and resiquimod in PBS. All vaccinations 
were given subcutaneously (SQ). At each time point, whole blood was collected from individual 
mice and stained with antibodies against CD3, CD8, CD44, and OVA dextramer. Samples were 
examined by flow cytometry, and the percent of OVA-specific CD8 T cells was obtained using 
the gating scheme shown in figure 11. The results are shown in figure 12 and are expressed as the 
mean (+/-) SEM percent of OVA-specific CD8 T cells as a function of time.  
Mice vaccinated with OVA and resiquimod in PCL-POE polymer had a slightly slower 
onset to peak response at day 13, with the average percent of OVA-specific CD8 T cells just 
above 1% of all CD8 T cells in the blood. This average percent was maintained within the range 
of 0.7 to 1.2 percent over the remaining time. While no statistically significant differences were 
seen between groups, mice receiving polymer-OVA-RES maintained, on average, peak levels of 
OVA-specific CD8 T cells for a period of 2 to 3 months before the onset of the contraction phase. 
The group of mice receiving OVA alone in PCL-POE polymer showed a mean peak percent of 
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OVA-specific CD8 T cells of 1.2 % on day 7 post-vaccination. This was followed by  contraction 
and maintenance phases typical of an acute infection. Surpisingly, mice vaccinated with four 
repetitive once daily boluses of OVA and resiquimod had a response that was similar to saline 
treated mice.  
In this study, mice receiving OVA and resiquimod in PCL-POE polymer appeared to be 
divided into two groups based on their response to the vaccine.  Thus, the mice were divided into 
“responders” or “non-responders”, based on the development of a peak percent of OVA-specific 
CD8 T cells above 1 %. The data for mice characterized as responders is plotted in figure 13 
where the percent of OVA-specific CD8 T cells is given as a function of time for each individual 
mouse. Mice, considered to be responders, achieved a peak OVA-specific CD8 T cell response of 
at least 1 %. At each time point measured, whole blood was collected from individual mice and 
stained with antibodies against CD3, CD8, CD44, and OVA dextramer. Samples were subjected 
to flow cytometry, and the percent of OVA-specific CD8 T cells was obtained using the gating 
scheme shown in figure 11, and the percentage of OVA-specific CD8 T cells in the blood is 
plotted versus time. The initial peak percent of OVA-specific CD8 T cells in the blood ranged 1 
to 5 % and occurred between 2 to 6 weeks post-vaccination. Three of four mice continued to 
maintain the percent of OVA-specific CD8s in their blood for the remainder of the measured time 
points. In mouse 2, the percentage of OVA-specific CD8 T cells in the blood continued to rise, 
reaching a secondary peak of approximately 7 % at 3 months post-vaccination, the last time point 
measured. 
There are a couple of potential explanations for the observed differences between 
responding and non-responding mice, discounting human error upon vaccine preparation or 
injection, and inconsistency in the rate of polymer degradation or OVA and resiquimod release. 
One possibility would be the occurrence in natural heterogeneity in the immune response to a 
vaccine. The natural tendency towards heterogeneity of an immune response to vaccine is 
implicated at multiple points in the development of the immune response. The number of naïve 
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antigen-specific CD8 T cells present in an antigen naïve mouse can vary by fifty to one hundred 
percent between mice. The average number of OVA-specific naïve CD8 T cells in Bl-6 mice can 
vary from approximately 50 to 200 cells.82 In addition, antigen-specific naïve CD8 T cells will 
proliferate between 10 and 13 times in response to antigen. This can lead to a 10-fold difference 
in the peak number of antigen-specific CD8 T in the blood stream on day 7 post-vaccination. 
These possibilities are supported by the clear difference in the magnitude and duration of the 
OVA-specific CD8 T cell response observed between “responders” and “non-responders”. Mouse 
2, a “responder”, is a perfect example of the difficulty we faced in predicting the release of OVA 
and resiquimod from the PCL-POE polymer in vivo and the associated CD8 T cell response 
observed. In this mouse alone, it is possible that the “secondary” peak we observed at around 
three months post-vaccination is a combination of a re-activation of OVA-specific memory CD8 
T cells due to a “secondary” burst release from the PCL-POE polymer.  
Another potential explanation for the heterogeneity of the responses is the unknowns 
created by working with a novel slow-release vaccine. Given the uncertainties associated with the 
rate and extent of antigen and adjuvant release from the polymer, it is possible that different mice 
may have experienced peak responses at unmonitored time points or that the trafficking of the 
cells to the tissues may have occurred at different times relative to vaccination in the individual 
mice. However, this possibility is less likely given that the majority of the mice showed either a 
solid response or lack thereof at each time point measured. That is, in only one mouse did we 
observe a response at one time point and not at the others or vice versa.    
Due to the lack of a quality reagent for detecting OVA-specific CD4 T cells, we limited 
our analysis of the OVA-specific immune response to that of OVA-specific B cells (and anti-
OVA antibodies) and OVA-specific CD8 T cells. However, the magnitude and persistence of the 
anti-OVA antibody response we observed is a good, albeit indirect, marker for the existence of an 
OVA-specific CD4 T cell response. The delay in the development and peak of antigen-specific 
antibodies occurs because B cells specific for a protein antigen cannot be activated to proliferate, 
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form germinal centers, or differentiate into plasma cells until they encounter a CD4 (helper) T 
cell that is specific for one of the peptides derived from that antigen. As discussed below, the 
prolonged time frame for activation and proliferation of CD4 T cells in mice treated with polymer 
vaccine suggests that the delay, seen in the peak antibody response as well as the prolonged 
duration of response, is likely a combination of secondary exposure of antigen-specific memory B 
cells to their cognate antigen as well as the initial activation of naïve antigen-specific B cells and 
their simultaneous interaction with activated helper CD4 T cells specific for the same antigen. 
The potential role of antigen-specific CD4 T cells on the stimulation of the humoral immune 
response in response to persistent release of antigen and adjuvant warrants further exploration as 
the necessary reagents become available.  
 
Overall Survival in Response to Vaccination with PCL-POE/lysate/RES Vaccine in a Mouse 
Model of Glioma 
 
To address the impact of the PCL-POE polymer-based vaccine on overall survival in a 
mouse model of glioma, mice were inoculated with a GL261 murine glioma cell line. Because 
this cell line contains thousands of potential antigens, developing a vaccine which would target 
these potential antigens required that we rely on another type of antigen, whole cell lysates, for 
incorporation into the vaccine. Although lysate-based vaccines were most clinically relevant at 
the time of these experiments, analysis of any antigen-specific T cell response to any 
peptide:MHC complex was not possible because the specific antigens within the lysates had yet 
to be identified.  
For this study (Fig. 14), we used an orthotopic glioma model in which we inoculated 
mice with a 1 µL suspension containing 15,000 GL261 cells into the right hemisphere of the 
brain, according to the coordinates provided. Tumor development and growth were assessed 
routinely by bioluminescent imaging (BLI). Glioma-bearing mice were euthanized when they 
developed symptoms such as hunching, listlessness or cranial deformation. Tumor presence and 
46 
 
rate of growth was verified by BLI imaging on days 3 and 7 post-inoculation, prior to treatment 
group randomization or vaccination. Mice were excluded from the study if there was an absence 
of tumor on either day or if the tumor intensity by BLI imaging was less than 105 
photons/cm2/sec. 
Whole cell lysate vaccinations were derived from GL261 cells grown in 5% O2 .83 Mice 
were vaccinated seven days after inoculation of GL261 glioma tumor cells (Fig. 14). Mice were 
divided into groups on the day of vaccination based on bioluminescent imaging (BLI) data. Mice 
were categorized as having either a low, medium, or high intensity tumor. Mice from a single 
intensity group were then divided randomly into treatment groups so that each treatment group 
contained mice with an average and range of tumor sizes (intensities). Treatment groups include 
(a) saline, (b) lysate and RES in PBS (lysate/RES; positive control) given as four repetitive once 
weekly doses, (c) polymer and lysate only (PCL-POE/lysate) given once, and (d) lysate and 
resiquimod in PCL-POE polymer (PCL-POE/lysate/RES) given once. Mice in the PCL-
POE/lysate/RES group received either one or two doses of the vaccine. Both groups received a 
single dose of polymer containing 10 million killed cells and 200 µg of RES on day 7 post-
inoculation. The group receiving 2 doses was vaccinated a second time two weeks following the 
first vaccination, again receiving 10 million cells and 200 µg of RES. Mice receiving lysate and 
resiquimod in PBS were given the same total dose of 10 million killed cells and 200 µg of RES. 
This dose was divided into four separate vaccinations and mice were vaccinated on days 7, 14, 
21, and 28 post-inoculation. All vaccinations were administered subcutaneously. 
In the glioma survival model (Figure 15a), complete remission (cure) was observed in 
one of six mice (16 %) receiving lysate only in PCL-POE polymer, in one of six mice (16 %) 
receiving two doses of lysate and resiquimod in PCL-POE polymer, and in three of fourteen mice 
(21 %) receiving one dose of lysate and resiquimod in PCL-POE polymer. The mice achieving 
complete remission were followed for an additional fifteen months. No signs or symptoms of 
relapse was observed in any of the mice at the time of sacrifice. No mice in any other group 
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survived beyond 81 days post-inoculation. Interestingly, there was no difference seen among any 
of the treatment groups in the length of median survival. Thus, mice appeared to either achieve 
complete remission (cure) or experienced no benefit from treatment. Bioluminescent imaging 
(BLI) data of mice receiving a single vaccination of lysate and resiquimod in PCL-POE polymer 
is shown in figure 15b. The results shown are from one of three independent experimental 
replicates. Mice achieving complete remission were sacrificed, and none showed any signs or 
symptoms of disease at the time of sacrifice.  
Perhaps surprisingly, observation of the survival data revealed that the value of a second 
vaccination with lysate and resiquimod in PCL-POE polymer was minimal, as percent overall 
survival in the group receiving one vaccination of lysate and resiquimod in PCL-POE polymer 
was 21 % as compared to 16 % of mice receiving a second dose. However, this data must not be 
over-interpreted given that the number of mice in the group receiving a second dose was only six 
and was only included in the last of the three replicates of the experiment. The second vaccination 
did appear to induce a temporary regression in a small percentage of mice treated (Fig 15c). 
However, despite the apparent regression induced by the second vaccination, the tumor quickly 
advanced within a period of eight to twelve weeks following the second vaccination resulting in 
death in all but the sole mice achieving complete remission. The lack of any significant 
improvement in survival with a second vaccination may indicate that past a certain point, 
providing further persistent antigen and adjuvant does not lead to further improvement in 
survival. However, additional replicates of this experiment may be necessary to better assess the 
value of adding a second dose of the polymer vaccine. 
Finally, we observed that the group of mice receiving lysate and resiquimod in PBS as 
four repetitive bolus vaccinations consistently experienced a faster rate of tumor growth (Figs 15d 
& 15e) and death than mice receiving saline control. These results were replicated in the three 
independent experiments. We believe that one potential explanation for this unexpected finding 
was the result of the different pharmacokinetics of resiquimod when given as a bolus vaccine as 
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compared to its incorporation into the PCL-POE semi-solid polymer. We hypothesized that the 
increase in local concentration and higher dose of RES resulting from a bolus dose of vaccine 
resulted in more widespread activation of TLR7/8 expressing cells of the immune system. In 
addition to neutrophils and dendritic cells of the innate immune system, which coordinate the T 
cell response to antigen, additional cells of the immune system have been found to express 
TLR7/8. One type of immunosuppressive cell, myeloid derived suppressor cells (MDSCs), has 
been shown to express the TLR7/8 receptor and to be activated in response to RES exposure.84,85 
An increase in the activation of MDSCs was shown to result in poorer survival rates in numerous 
pre-clinical86 and human cancers.87,88 It is possible that delivery of RES by its incorporation into 
the polymer vehicle resulted in lower local concentrations of RES and therefore a decrease in the 
number of MDSCs and/or an increase in the ratio of DCs to MDSCs that are activated. Future 
studies to determine the effect of RES doses and vaccination regimens on the preferential 
activation of different immune cells will be necessary to optimize the overall potential of this 
adjuvant and the timing of its release from polymer vehicles. 
 
Non-specific CD4 and CD8 T-cell response to PCL-POE/lysate/RES Vaccine 
As discussed above, the GL261 glioma cell line contains thousands of potential antigens. 
Therefore, we utilized a whole cell lysate vaccine developed from the same tumor cell line in 
order to stimulate an anti-tumor T cell response specific for GL261 antigens. Although lysate-
based vaccines are a clinically relevant form of anti-cancer vaccine, analysis of the antigen-
specific T cell response to any specific peptide:MHC complex is not possible because the specific 
antigens within the lysates have yet to be identified. Therefore, to understand the link between the 
vaccine-induced immune response kinetics and overall survival, a method for detecting the T cell 
response to the lysate vaccine was needed. For this, we relied upon a non-specific method for 
detecting activated (proliferating) T cells, which allowed measurement of the CD4 T cell 
response in addition to the CD8 T cell response.  
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The method relies upon use of the nuclear protein Ki67. When cells are actively 
proliferating, the nucleus up-regulates the protein Ki-67, which is strictly a marker of 
proliferating cells. During interphase, the Ki-67 antigen can be exclusively detected within the 
cell nucleus, whereas in mitosis most of the protein is relocated to the surface of the 
chromosomes. Ki-67 protein is present during all active phases of the cell cycle (G1, S, G2, and 
mitosis) but is absent from resting cells (G0).89 Thus, Ki67 is an excellent marker for determining 
the so-called growth fraction of a given cell population.90 In an average, healthy cell population, 
such as CD4 or CD8 T cells, the average expression of Ki67 ranges from three to ten percent of 
the cells.91 In cells that are activated to proliferate, as would be the optimal response of immune 
cells to a vaccine, the percentage of cells of a single type, ideally CD4 or CD8 T cells that are 
expressing Ki67 would be expected to increase sharply beyond that of non-proliferating cells. 
Therefore, we used Ki-67 as a marker for the ability of the PCL-POE/lysate/RES vaccine to 
activate CD4 and CD8 T cells.  
Although the mice are housed and treated under sterile conditions, the immune system is 
continually responding to minor antigens, and thus there remains the possibility that non-tumor 
specific T cells are proliferating in response to non-tumor antigens. Therefore, use of a saline 
treated group of mice as a negative control allowed detection of the relative percentage of CD4 
and CD8 T cells that were activated in response to PCL-POE/lysate/RES vaccination. 
In this study, we vaccinated tumor-bearing mice seven days after they had been 
inoculated with glioma cells (Fig. 14). Groups of mice that underwent immune analysis were 
vaccinated with (a) saline, (b) lysate and RES in PBS (lysate/RES; positive control) given as four 
repetitive once weekly doses, (c) polymer and lysate only (PCL-POE/lysate) given once, and (d) 
lysate and resiquimod in PCL-POE polymer (PCL-POE/lysate/RES). The results of this study are 
shown in figures 16a and 16b. Figure 16a shows the percentage of proliferating, Ki67+ CD8 T 
cells, at two week intervals starting at day 7 post-vaccination. The group of mice vaccinated with 
lysate and resiquimod given as four repetitive once weekly doses showed a weak peak at day 7 
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post-vaccination that was very similar to the increase in KI67+ proliferating CD8 T cells that was 
seen in the saline treated group. However, this group developed a “secondary” peak on day 21 
post-vaccination that was statistically greater compared to the saline treated group (p < 0.05). The 
marginal increase in the percent of proliferating CD8 T cells observed in saline treated mice is 
likely the result of local inflammation at the injection site.  
Mice treated with lysate and resiquimod in PCL-POE polymer developed a peak percent 
of Ki67+ cells on day 7 post-vaccination that was greater than that of mice receiving soluble 
vaccinations. It was our expectation that mice receiving the four consecutive bolus lysate/RES 
vaccines would have a higher percentage of proliferating CD8 T cells on day 7 post-vaccination 
because, as previously stated, this is the time of the peak response in the blood after an acute 
infection, which is most closely resembled by the bolus vaccinations. However, the percentage of 
KI67+ cells in this group underwent a contraction phase after the day 7 peak, reaching baseline 
levels at 5 weeks post-vaccination. This represents a stark contrast to the extended duration of 
time over which OVA-specific CD8 T cells were maintained in the blood following initial 
vaccination with OVA and resiquimod in PCL-POE polymer. This difference may be a 
consequence that vaccinations were injected into tumor-bearing mice. The glioma-specific CD8 T 
cells that were activated and had undergone rapid proliferation and differentiation to effector CD8 
T cells would acquire the ability to traffic into the tissues; in this case, the brain and to the site of 
the target glioma cells. Thus, the percentage of cells present in the blood in the presence of 
disease is not the best indicator of the immune response to the vaccination. However, given the 
trafficking of effector cells via the blood stream on their way to the target site, the data obtained 
from blood analysis still provides some value, because the correlation between the percentage of 
proliferating CD8 T cells in the blood and overall survival in glioma can be assessed. 
The CD4 T cell response to vaccination is shown in figure 16b. Mice vaccinated with 
GL261 lysate and resiquimod in PCL-POE polymer developed a slow response to vaccine, 
exhibited by the percent of Ki67+ cells in the blood on day 7 that was less than that of saline 
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treated mice. However, mice in the polymer group developed a delayed peak response, 
demonstrated by a statistically significant increase in the percentage of proliferating CD4 T-cells 
in the blood on day 21 as compared to mice vaccinated with weekly bolus injections of GL261 
lysates and resiquimod. Mice treated with weekly bolus injections of GL261 lysates and 
resiquimod showed no difference in the percent of Ki67+ CD4 T cells in the blood at any time 
point compared to saline treated mice. 
The CD8 and CD4 T cell responses were consistent with previous reports showing that 
antigen-specific CD8 T cells are best activated by a single, acute dose of vaccine (or exposure to 
pathogen), while CD4 T cell responses are slower to develop a response to the same level of 
antigen exposure.92 CD8 T cells are intrinsically programmed to have a faster rate of cell division 
than CD4 T cells due to the expression kinetics of cell-cycle derived growth factors.93 In addition, 
the duration of antigen exposure required to stimulate rapid proliferation of naïve antigen-specific 
CD8 T cells has been shown to be much less than that required for naive antigen-specific CD4 T 
cells.94, 95 The results observed in the above experiment are consistent with these findings. It is 
possible that vaccinating with repetitive bolus doses of lysate and resiquimod vaccine once 
weekly resulted in an initial CD8 T cell response similar to that of an acute infection. Over the 
first week post-vaccination, memory CD8 T cells would start to develop, such that each of the 
next three weekly vaccinations would stimulate a secondary immune response to the lysate 
antigens, exemplified by the later peak in percent of Ki67+ CD8 T cells observed in this group on 
day 21 post-vaccination. The group achieving the greatest percent of Ki67+ CD4 T cells also 
experienced the peak response on day 21 post-vaccination. Again, this observation coincides with 
the evidence discussed above in that CD4 T cells have a slower intrinsic response to antigen 
exposure and also require a longer duration of antigen exposure in order to undergo a rapid 
proliferation response.  
The difference between the soluble and polymer vaccines and the timing of their injection 
allow further inferences regarding the rate and mechanisms of antigen and adjuvant release from 
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the PCL-POE polymer in vivo. It seems likely that, following an initial burst release of lysate 
antigen and RES, the remainder of each is released at a slower and continuous rate. It remains 
possible that the slow and persistent release of the antigen and adjuvant is providing a secondary 
exposure of antigen to antigen-specific memory T cells that have formed. It is also reasonable that 
the number of memory cells was slowly accumulating with time as additional antigen (lysate)-
specific naïve T cells are activated upon their initial exposure to antigen. This creates a scenario 
in which the PCL-POE/lysate/RES vaccine is continuously activating and re-activating antigen-
specific cells with the persistent release of antigen and adjuvant from the polymer. Future studies 
of the effect of a slow release polymer on proliferating CD4 and CD8 T cells are required in order 
to best understand the kinetics of the immune response.  
 
Correlation Between Vaccine-induced T Cell Response and Overall Survival  
Although the primary aim of this work was to develop an efficacious vaccine for 
treatment of glioma, we additionally assessed the connection between the magnitude of the CD4 
and CD8 T cell responses and overall survival in our mouse model of glioma. Using data from 
our survival experiment and immune response monitoring, we plotted the average percentage of 
Ki67 expressing CD8 (Fig. 17a) and CD4 (Fig. 17b) T cells over time in mice characterized as 
survivors, those in which a relapse was not observed following complete remission, and non-
survivors. Data shown are compiled from the survival and immune response data from the 
experiment shown in figure 14. As the immune response to mice receiving two doses of PCL-
POE/lysate/RES vaccine was not monitored, the mouse achieving complete remission in that 
group was not included in this analysis. Although there was no statistically significant correlation 
between the percent of Ki67+ CD8 T cells and survival, there was an observable difference 
between survivors and non-survivors on day 14 post tumor inoculation, 7 days after the initial 
vaccination. The percent of Ki67+ CD8 T cells in the blood of survivors declined over the next 
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few weeks, showing no difference in response compared to the non-survivors at any other time 
point measured.  
Mice undergoing complete tumor remission (survivors) had an observable increase in the 
percent of Ki67+ CD4 T cells in the blood at each time point measured as compared to non-
survivors. The biggest difference was seen on day 21 post-vaccination (day 28 post-tumor cell 
inoculation), as the percent of Ki67+ CD4 T cells in the blood of survivors was approximately 17 
% as compared to approximately 12 % in non-survivors. This difference reached statistical 
significance (p < 0.05).  
The peak in percent of proliferating CD4 T cells observed in the group vaccinated with 
lysate and resiquimod in PCL-POE polymer appeared to have an effect on overall survival. In 
contrast, the peak in percent of proliferating CD8 T cells observed in mice receiving repetitive 
once weekly bolus vaccinations of lysate and resiquimod did not appear to have a positive effect 
on survival. This finding is of particular interest because evidence from Nelson, et al96 
demonstrated that in a chronic infection of Salmonella typhimurium, continuous and local 
“release” of antigen at low levels resulted in a more stable antigen specific CD4 T cell response 
in which the development and persistence of memory CD4 cells was prolonged compared to that 
of an acute exposure to antigen. In addition, studies of cancer and chronic viral infections have 
shown that the presence of a strong CD4 response is an important factor in alleviating the onset of 
CD8 T cell exhaustion.97,98 
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CONCLUSION 
Glioblastoma multiforme is a primary and devastating malignancy of the central nervous 
system. GBM, along with many other solid tumors, continue to have extremely poor prognoses 
despite the extensive research dedicated to finding a cure. Immunotherapy is a growing area of 
research that presents a novel approach for achieving a cure. The central premise for the use of 
anti-tumor vaccines is the potential of complete eradication cancer cells at the tumor site. The 
potential for tumor-specific immune cells to identify tumor cells beyond the visible mass provides 
support to the idea that a complete cure is possible. The reasons behind the current lack of success 
of anti-cancer vaccines are innumerable, ranging from poor choice of vaccine components to the 
presence of the immunosuppressive tumor environment. Here we have attempted to address the 
role of antigen persistence and altering the quantitative and qualitative nature of the immune 
response through the use of a novel PCL-POE polymer vaccine.  
We have shown that the in vitro release of antigen and adjuvant from PCL-POE polymer 
was dependent upon the physiochemical characteristics of the antigen and adjuvant incorporated. 
We observed a burst release of both antigen and adjuvant that was likely the result of the high 
concentration of antigen and adjuvant that were incorporated into the polymer. In the both cases, 
the initial burst release was followed by a much slower phase of release over the next three 
weeks.  
Incorporating antigen and adjuvant into the PCL-POE polymer as a vaccine allowed 
measurement of the effects of antigen and adjuvant release rates on the innate and adaptive 
immune responses. With the innate immune system, we observed that the slow release provided 
by the PCL-POE polymer stimulated the maturation of dendritic cells for a period of at least two 
weeks following a single vaccination. This was exemplified by the increased expression of 
MHCII and co-stimulatory molecule CD86 on the surface of the DCs. We also observed an 
intrinsic adjuvant effect of the polymer itself, as injection of the polymer alone caused an 
increased expression of MHCII and co-stimulatory molecule CD86 on the surface of the DCs.  
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Persistent antigen and adjuvant release from the polymer led to the development of a 
potent and long-lasting anti-OVA antibody response. This was perhaps most striking with the 
PCL-POE polymer vaccine. Given the vital role of antibodies in containing and eliminating 
disease, we believe that this finding supports further investigation of the cause and effect 
relationship between the rate and extent of antigen and adjuvant release and the stimulated 
antibody response. Future studies to determine the rate of conversion of naïve antigen-specific B 
cells into the effector cells, including memory B cells, short-lived plasma cells and long-lived 
plasma cells will be necessary in order to understand the effect of persistent vaccine antigen on 
the kinetics of this physiological process. In addition, studies of the rate of change of antibody 
affinity with time would allow for further understanding how persistent vaccine antigen alters the 
relative portions of antigen-specific naïve B cells that differentiate down the three different B cell 
effector pathways. 
Finally, we have shown that mice vaccinated with antigen and adjuvant delivered by the 
PCL-POE polymer experienced a significant, potentially translatable increase in overall survival 
in a mouse model of glioma. Although the median survival was not improved with this treatment, 
twenty percent of mice treated with the polymer vaccine achieved long-term remission and a 
probable cure. This finding is consistent reports emanating from current clinical trials of 
immunotherapies in humans.99 Of further interest was the finding of a correlation between the 
percent of proliferating CD4 T cells in response to vaccination and overall survival. This finding 
warrants further investigation given the evidence showing the positive effect of persistent antigen 
on the CD4 T cell response, the value of a strong CD4 response is an important factor in 
alleviating the onset of CD8 T cell exhaustion, and the direct role that CD4 T cells have shown in 
elimination of cancer and infected cells.100,101 
Future work is necessary to better understand the effect of persistent antigen on the 
quantitative and qualitative nature of the anti-tumor immune response. In addition, considerable 
effort will be needed to unravel the effect of altered immune response kinetics, stimulated by 
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persistent antigen and adjuvant, on the mechanisms and effectiveness of tumor cell killing.  
Nevertheless, these findings have helped to clarify the link between persistent antigen provided 
by a polymer-based vaccine and survival in glioma and hopefully will stimulate further work to 
reach the ultimate goal of curing glioblastoma. 
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Figures 
 
 
Figure 1) Schematic diagram of the antigen processing and cross presentation pathway in 
dendritic cells (DCs). Left) Viruses are internalized and processed in DCs; antigens are then 
shuttled to the endoplasmic reticulum (ER) and cross-presented by DCs through the MHC-I and 
MHC-II complexes.  (Middle) CD4 cells (T-helper cells) recognize MHC-II presentation causing 
proliferation of CD4 cells and signaling CD8 cells.  (Right) CD8 cells (killer cells) recognize 
MHC-I presentation and kill the organism. 
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Figure 2) Schematic diagram of poly-(ε-caprolactone)-poly-(ortho ester) [PCL-POE] polymer 
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Figure 3a) Cumulative mean (+/- SD) percent release of Ovalbumin protein (OVA) from the 
PCL-POE polymer as a function of time.  Experimentally, 1000 µg of OVA and 200 µg of RES 
were combined with 200 µl of the polymer and then placed into 10 mL of PBS in a 50 mL conical 
tube. The sample was then incubated at 37 °C while rotating at 200 RPMs.  At each indicated 
time point, 2 mL of supernatant was collected and replaced with 2 mL of fresh PBS. The amount 
of OVA contained in each sample was estimated by the Bradford BCA (Pierce) protein 
quantification kit. The experiment was performed in triplicate.  
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Figure 3b) Cumulative mean (+/- SD) percent release of resiquimod from the PCL-POE polymer 
as a function of time. Experimentally, 1000 µg of OVA and 200 µg of RES were combined with 
200 µl of the polymer and placed in to 10 mL of PBS in a 50 mL conical tube.  The sample was 
then incubated at 37° C while rotating at 200 RPMs. At each indicated time point, 2 mL of 
supernatant was collected and replaced with 8 mL of fresh PBS. This process was repeated for 
each time point. The amount of RES in each sample was measured using liquid chromatography-
mass spectrometry (LC-MS). The experiment was performed in triplicate.  
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Figure 4) Schematic diagram of the experimental protocol used in comparing the OVA-specific 
CD8 T cell response to two adjuvants, resiquimod and polyI:C given as a bolus or polymer 
vaccine. Resiquimod treatment groups included OVA 200 µg and RES 50 µg in PBS (OVA-RES 
x4; positive control) given as four repetitive once daily doses, PCL-POE polymer and OVA 800 
µg plus resiquimod 200 µg (polymer-OVA-RES) given once. PolyI:C treatment groups included 
OVA 200 µg and polyI:C 50 µg in PBS (OVA-polyI:C x4; positive control) given as four 
repetitive once daily doses, PCL-POE polymer and OVA 800 µg plus polyI:C 200 µg (polymer-
OVA-polyI:C) given once. All vaccinations were given subcutaneously. OVA-specific CD8 T 
cell percentages were measured by flow cytometry on days 7, 14, 21, 28, 35, 45, and 100 post-
vaccination. 
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Figure 5a) Percent OVA-specific CD8 cells as a function of time for mice vaccinated with either 
(Red) OVA+polyI:C in PBS given subcutaneously as four repetitive once daily bolus injections 
or (Blue) OVA+polyI:C in PCL-POE given as a single subcutaneous injection. Total doses for 
OVA and polyI:C were equivalent in both groups.  
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Figure 5b) Percent OVA-specific CD8 cells as a function of time for mice  vaccinated with either 
(Red) OVA+RES in PBS given subcutaneously as four repetitive once daily bolus injections or 
(Blue) OVA+RES in PCL-POE given as a single subcutaneous injection. Total doses for OVA 
and RES were equivalent in both groups.  
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Figure 5c) Percent OVA-specific CD8 cells as a function of time for mice vaccinated with PCL-
POE polymer containing OVA protein and either (Blue) RES or (Red) polyI:C adjuvant. Both 
vaccinations were given as a single subcutaneous dose, and the total dose of OVA and the dose of 
either RES or polyI:C were equivalent in both groups. The dashed line represents the mean 
percent of  naïve OVA-specific CD8 T cells in a saline treated B6 mouse.  
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Figure 6) Schematic diagram of Kb:OVA dextramer method of identification of OVA-specific 
CD8 T cells. The Kb:OVA dextramer reagent used for identification of OVA-specific CD8 T cells 
consists of a multimer of biotin-conjugated MHCI molecules specific for SIINFEKL. The 
SIINFEKL peptide is loaded into the MHCI protein, and the monomer units are bound together 
by conjugation to a streptavidin core. The dextramer reagent mimics the OVA:MHCI-specific 
CD8 T cell receptor binding to the OVA:MHCI presented on the surface of dendritic cells. 
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Figure 7) Schematic diagram of the experimental protocol used for vaccination and measurement 
of dendritic cell maturation in vivo. Treatment groups include saline, OVA 200 µg and RES 50 
µg in PBS (OVA-RES x4; positive control) given as four repetitive once daily doses, PCL-POE 
polymer and OVA 800 µg only (polymer-OVA) given once, and PCL-POE polymer and OVA 
800 µg plus resiquimod 200 µg (polymer-OVA-RES) given once. On days 7 and 14 post-
vaccination, mice were sacrificed and the draining lymph nodes were harvested. The maturation 
of DCs, characterized by the percent expressing MHCII, CD80, and CD86 was measured by flow 
cytometry. DCs were initially separated by expression of CD11c. 
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Figure 8 (a) Vaccination and Monitoring Scheme for Study of Dendritic Cell Maturation. (b) 
Induction and maintenance of DC maturation by vaccination with PCL-POE/OVA/RES, where 
the percentage of dendritic cells expressing MHCII, CD80, and CD86 is given on days 7 and 14 
post-vaccination.  
 
 
 
 
68 
 
 
Figure 9) Schematic diagram of the experimental protocol used for vaccination and anti-OVA 
antibody and OVA-specific CD8 T cell monitoring of mice vaccinated with OVA and RES as a 
bolus or incorporated into the PCL-POE polymer. Treatment groups include saline, OVA 200 µg 
and RES 50 µg in PBS (OVA-RES x4; positive control) given as four repetitive once daily doses, 
PCL-POE polymer and OVA 800 µg only (polymer-OVA) given once, and PCL-POE polymer 
and OVA 800 µg plus resiquimod 200 µg (polymer-OVA-RES) given once. All vaccinations 
were given subcutaneously. Anti-OVA antibodies were measured by ELISA on days 13, 20, 27, 
34, and 48 post-vaccination. OVA-specific CD8 T cell percentages were measured by flow 
cytometry on days 5, 7, 9, 13, 20, 27, 34, and 48 post-vaccination. 
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Figure 10) Optical density measurements reflecting OVA-specific IgG and IgM antibodies.  
C57BL/6J (B6) non-tumor bearing mice were vaccinated with OVA antigen and resiquimod in 
the PCL-POE polymer administered as a single subcutaneous injection, OVA antigen alone in the 
PCL-POE polymer administered as a single subcutaneous injection, OVA and resiquimod in PBS 
given subcutaneously and repetitively as four consecutive daily bolus injections (positive 
control), or saline. The total dose of OVA and/or resiquimod given was the same in all groups. At 
the time points indicated, plasma was collected from individual mice and analyzed for the 
presence of OVA-specific IgG and IgM antibodies by ELISA. All samples were run in triplicate 
and an average result recorded for each individual mice. The results shown are the mean and 
standard error of the mean (SEM) of each treatment group.  
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Figure 11) Representative figures indicating the gating zones used in the analysis of the flow 
cytometry data for identifying (left) lymphocytes, (center) CD8+ cells, and (right) OVA-specific 
CD8 T cells.  
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Figure 12) OVA-specific CD8 T cell response in blood of vaccinated mice with values expressed 
as the mean + SEM percent of OVA-specific CD8 T cells as a function of time.  
72 
 
 
Figure 13) Time-dependent percentages of OVA-specific CD8 T cells in the blood of 
“responders”. C57BL/6J (B6). Non-tumor mice were vaccinated and those considered as 
responders achieved a peak OVA-specific CD8 T cell response of at least 1 %. At the time points 
indicated, whole blood was collected from individual mice and analyzed by flow cytometry 
according to the indicated protocol.  
 
 
 
73 
 
 
Figure 14) Schematic diagram of the experimental protocol for Glioma Tumor Challenge and 
Immune Monitoring in Tumor-bearing mice. Mice were inoculated with 15,000 GL261 cultured 
tumor cells on day 0. Tumors were confirmed with bioluminescent imaging on days 3 and 7 post-
inoculation. Whole cell lysate vaccinations were derived from GL261 cells grown in 5% O2. 
Treatment groups include saline, lysate and RES in PBS (lysate/RES; positive control) given as 
four repetitive once weekly doses, polymer and lysate only (PCL-POE/lysate) given once, and 
lysate and resiquimod in PCL-POE polymer (PCL-POE/lysate/RES).  
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Fig 15a) Overall Survival in Glioma-bearing Mice Treated with Experimental Vaccine.                  
Results shown are pooled data from three independent experiments. Mice were inoculated with 
glioma tumor cells and treated as described.  
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Figure 15b) Bioluminescent Imaging Data of Mice Given a Single Vaccination of Lysate and 
resiquimod in PCL-POE polymer. Images shown are the results from one of three independent 
experimental replicates. The two mice on the far right were long-term survivors.  
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Figure 15c) Time-dependent bioluminescent imaging intensity data of mice treated with two 
doses of lysate and resiquimod in the PCL-POE polymer. 
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Figure 15d) Time-dependent bioluminescent imaging intensity data of mice treated with lysate 
and resiquimod in the PCL-POE polymer, lysate and resiquimod given as four repetitive once 
weekly boluses, and saline. 
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Figure 15e) Time-dependent bioluminescent images of mice treated with lysate and resiquimod 
given as four repetitive once weekly boluses. 
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Figure 16a) CD8 T cell Activation and Proliferation in Response to Treatment with Whole Cell 
Lysate Vaccines. Tumor-bearing mice were vaccinated seven days after they had been inoculated 
with glioma cells as shown in figure 12. Mice were vaccinated with saline, lysate and RES in 
PBS (lysate/RES; positive control) given as four repetitive once weekly doses, polymer and lysate 
only (PCL-POE/lysate) given once, or lysate and resiquimod in PCL-POE polymer (PCL-
POE/lysate/RES). The results shown are the percentage of proliferating, Ki67+ CD8 T cells, at 
two week intervals starting at day 7 post-vaccination. The dashed black line represents the 
average number of Ki67+ cells in untreated B6 mice.  
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Figure 16b) CD4 T cell Activation and Proliferation in Response to Treatment with Whole Cell 
Lysate Vaccines. Tumor-bearing mice were vaccinated seven days after they had been inoculated 
with glioma cells as shown in figure 12. Mice were vaccinated with saline, lysate and RES in 
PBS (lysate/RES; positive control) given as four repetitive once weekly doses, polymer and lysate 
only (PCL-POE/lysate) given once, or lysate and resiquimod in PCL-POE polymer (PCL-
POE/lysate/RES). The results shown are the percentage of proliferating, Ki67+ CD8 T cells, at 
two week intervals starting at day 7 post-vaccination. The dashed black line represents the 
average number of Ki67+ cells in untreated B6 mice.  
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Fig 17a) Correlation Between the Percentage of Ki67+, proliferating, CD8 T cells and Survival in 
a mouse glioma model. Data shown are compiled from the survival and immune response data 
from the experiment shown in figure 12. Data are plotted as the percent of Ki67+ CD8 T cells in 
the blood over time, separated by survivor status. The dashed line is the average percentage of 
Ki67+ CD8 T cells in the blood of untreated mice. 
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Fig 17b) Correlation Between the Percentage of Ki67+, proliferating, CD4 T cells and Survival in 
a mouse glioma model. Data shown are compiled from the survival and immune response data 
from the experiment shown in figure 12. Data are plotted as the percent of Ki67+ CD4 T cells in 
the blood over time, separated by survivor status. The dashed line is the average percentage of 
Ki67+ CD8 T cells in the blood of untreated mice. 
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